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Abstract 
Connexin26 (Cx26) and Cx30 facilitate gap junctional intercellular communication (GJIC) in 
the epidermis and are linked to several syndromic skin diseases. We investigated 5 disease-
linked Cx26 mutants and demonstrated that the severity and extent of disease can be predicted 
from the gain- or loss-of function properties of each mutant, as well as the ability to induce 
cell death. We also used transgenic mice expressing S17F Cx26 (linked to keratitis-ichthyosis-
deafness syndrome) or A88V Cx30 (linked to Clouston Syndrome) to investigate the 
pathophysiology these skin diseases. We demonstrated that S17F Cx26, but not A88V Cx30, 
promotes palmoplantar keratoderma by disrupting keratinocyte differentiation. Primary 
keratinocyte cultures from these mice demonstrated the mutants can also affect gap junction 
intercellular communication and cell migration. Lastly, we showed that mutant mice retain 
most wound healing properties. Together, we suggest that syndromic mutants often display 
gain-of-function properties and can disrupt keratinocyte differentiation in the epidermis. 
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Chapter 1 
1.1 Introduction  
1.1.1 Structure, Function and Life-Cycle of Connexins and Gap Junctions 
Gap junctions are multimeric transmembrane channels that allow adjacent cells to 
communicate via the exchange of ions and small molecular messengers less than 1 kDa 
(Alexander and Goldberg, 2003). Gap junctions and their individual connexin monomers have 
been studied extensively since their discovery and characterization in the 1960’s (Revel and 
Karnovsky, 1967). Cellular communication through gap junction channels plays an important 
role in cell physiology and these molecules have proven indispensable to human health (Garcia 
et al., 2016b). Connexins are 4-pass transmembrane proteins that can be found in nearly all 
cell types in humans (Laird, 2006). Every connexin molecule contains cytosolic amino (NT) 
and carboxy termini (CT), 2 extracellular loops (E1, E2), and one intracellular loop (IL) which 
serve specific roles to make a functional gap junction channel with various properties of 
molecular selectivity, channel gating, docking compatibility, and trafficking (Yeager and 
Harris, 2007). For example, the crystal structure of the Cx26 channel demonstrates that the 
NT can be located inside the pore suggesting it acts like a plug controlling channel gating and 
molecular selectivity (Maeda et al., 2009). Furthermore, Cx26 has a smaller pore size 
compared to other connexins (e.g. Cx43) which restricts molecular permeability (Weber et al., 
2004).  
Connexins are named according to their molecular weight in kDa: for example, connexin26 
(Cx26) is approximately 26 kDa. They are organized into compatibility subgroups in which 
members can oligomerize to form mixed channels that have distinct channel properties from 
channels composed of the individual connexin types; for example Cx26 and Cx30 can intermix 
in connexons and gap junctions (Richard, 2000). Homomeric and heteromeric channels differ 
because they are composed of one or multiple connexin types, respectively (Richard, 2000). 
This variability dramatically increases the number of channel possibilities and intercellular 
communication characteristics in cells expressing multiple connexins – further reinforcing 
their complexity in cellular communication.  
!!
2!
Connexins are co-translationally inserted into the endoplasmic reticulum and travel to the 
Golgi apparatus where many oligomerize to form connexons (Musil and Goodenough, 1993). 
Small vesicles containing connexons traffic and fuse with the plasma membrane where they 
may function as un-docked hemichannels to couple the cell to the extracellular milieu 
(Goodenough and Paul, 2003). When a connexon docks with another from an adjacent cell, a 
gap junction channel is formed, which allows for signaling molecules to pass between the 
cytosol of both cells in a process called gap junctional intercellular communication (GJIC) 
(Goodenough and Paul, 2009). Gap junction channels often tightly cluster in the plasma 
membrane to form highly organized structures called gap junction plaques which create an 
appositional region with a high degree of cytosolic coupling. Some connexins can be 
phosphorylated to influence channel function (Lampe and Lau, 2004) or bind with any number 
of intracellular proteins suggesting they may have additional non-channel functions (Laird, 
2006). For example, the C-terminus of Cx43 is known to bind  to several intracellular proteins 
including a specific domain of the zona-occludens-1 protein which is best known to be 
involved in the formation of tight junctions (Giepmans and Moolenaar, 1998; Toyofuku et al., 
1998). These findings suggest gap junctions at the membrane may also support intercellular 
adhesion in addition to communication (Prochnow and Dermietzel, 2008). Gap junction 
plaques can vary greatly in size (Zampighi et al., 1989) and composition wherein different 
channel types are known to mix, or form separate clusters within a larger combined plaque 
(Kelly et al., 2015). Gap junctions generally have a half-life of 2 to 5 hours (Beardslee et al., 
1998; Fallon and Goodenough, 1981) and it is thought that their rapid turnover and reassembly 
allows the cell to respond quickly to disruptions in tissue homeostasis by making necessary 
changes in the level of GJIC: for example, following tissue injury (Churko and Laird, 2013).  
1.1.2 Connexin Gene Mutations and Human Disease 
Twenty-one members exist in the connexin family and all have distinct, yet often overlapping 
tissue expression profiles, suggesting they are critical to human physiology (Avshalumova et 
al., 2014; van Steensel, 2004). Furthermore, connexin gene mutations have been linked to 
many human pathologies including skin disorders, hearing loss, cardiopathies, 
neurodegenerative diseases, bone and cartilage abnormalities, and cataracts (Garcia et al., 
2016b).  Due to the complexity of the connexin life cycle, connexin mutations can affect their 
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intracellular trafficking, hemichannel function, gap junction function, stability at the cell 
membrane, or even compatibility with other connexins (Garcia et al., 2016a; Kelly et al., 2014; 
Scott et al., 2012). Not surprisingly, connexin gene mutations often result in disease affecting 
multiple tissues that express the specific connexin (Garcia et al., 2016b). This is exemplified 
in patients harbouring GJB2 mutations that have hearing loss with the comorbidity of skin 
disease due to the expression of Cx26 in both the inner ear and epidermis (Arita et al., 2006; 
de Zwart-Storm et al., 2008b; Martin and van Steensel, 2015; Richard et al., 2004). In addition, 
some connexin mutants produce no disease at all, likely because connexins have the ability to 
compensate for others within the same subgroup (Zheng-Fischhofer et al., 2007). This 
phenomenon is evident in the case of the Bart-Pumphrey Syndrome-causing N54K Cx26 
mutant in the skin, which lowers Cx26 expression, but is compensated by an increased 
expression of Cx30 (Richard et al., 2004). Human epidermis expresses 7 connexin proteins in 
overlapping stages of keratinocyte differentiation including Cx26, Cx30, and Cx43, making 
the skin an extremely complex tissue in terms of intercellular communication. (Di et al., 2001; 
Martin et al., 2014). Due to the dynamic nature of this outward-facing stratified epithelium, a 
high level of intercellular communication is likely required to coordinate the correct balance 
of keratinocyte proliferation and differentiation. 
1.1.3 Epidermal Physiology 
Human and mouse epidermis (Fig. 1.1) consist of four principle strata of keratinocytes; the 
stratum basale, stratum spinosum, stratum granulosum, and stratum corneum which faces the 
external environment (Menon et al., 2012). Highly proliferative basal keratinocytes detach 
from the underlying basement membrane and undergo a ~14-day terminal differentiation 
program as they transition through the epidermal layers (Candi et al., 2005; Segre, 2006). 
Keratinocytes of the stratum spinosum synthesize keratin filaments that form an extensive 
cytoskeleton to provide mechanical strength to cells (Segre, 2006). Keratinocytes of the 
stratum granulosum produce intracellular keratohyaline granules and lamellar bodies that 
release structural proteins and ceramides which further provide cells with mechanical strength 
and hydrophobicity. An important keratin filament aggregating protein, filaggrin, is released 
from keratohyaline granules and condenses the keratin cytoskeleton of differentiating 
keratinocytes to form flat sheet-like cells (Sandilands et al., 2009). Additionally, filaggrin is  
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Figure 1.1 
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Figure 1.1. Connexin protein expression in unwounded and wounded mouse epidermis. 
Adult epidermis is composed of 4 layers of keratinocytes (stratum basale, stratum spinosum, 
stratum granulosum, stratum corneum) which express up to 7 distinct connexin proteins in 
overlapping distribution patterns. Notably, Cx43 is expressed mostly in the stratum spinosum 
and in some cells of the stratum basale, while Cx26 and Cx30 are weakly expressed in the 
stratum granulosum. Twenty-four hours after an epidermal wound, Cx26 and Cx30 are 
expressed in keratinocytes at the wound margins, whereas Cx31.1, Cx40, and notably, Cx43 
are markedly downregulated in keratinocytes at the wound margin. Figure used with 
permission from Dr. Jared Churko.  
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degraded by proteases in the stratum corneum into free amino acids and derivatives which 
constitute the skin’s natural moisturizing factor (Sandilands et al., 2009). Terminal 
differentiation involves a specialized form of apoptosis, called cornification (Eckhart et al., 
2013), whereby keratinocytes transition into enucleate flattened cells, which amongst many 
layers, weave together to form a protective external covering (Menon et al., 2012). Between 
interlocked corneocytes is a mortar of hydrophobic ceramides that generates an effective 
outward-in waterproof barrier (Menon et al., 2012). Together these layers give the epidermis 
its structural integrity, resiliency to damage, and impermeability to water and microbes (Segre, 
2006). It is important to note that the epidermis (especially the stratum corneum) varies greatly 
in thickness between volar skin where it is thickest, and dorsal skin where it is considerably 
thinner (Segre, 2006). Epidermal thickness may correlate with the amount of mechanical stress 
endured by each anatomical region of skin.  
A key factor thought to be involved in keratinocyte differentiation is an increasing calcium 
(Ca2+) gradient found between cells of the stratum basale and granulosum (Bikle et al., 2012). 
Approximately 2µM of Ca2+
 
are found in the basal layer which triple by the granular layer, 
and fall to very low levels in the stratum corneum (Behne et al., 2011). Hemichannels have 
been shown to release adenosine triphosphate (ATP) that can influence purinergic signaling 
and intracellular Ca2+ handling in an autocrine/paracrine fashion (Baroja-Mazo et al., 2013), 
which may affect the natural calcium gradient. Furthermore, GJs regularly permit the passage 
of inositol-trisphosphate (IP3) (Alexander and Goldberg, 2003) which is known to affect Ca2+ 
mobilization, and is likely important in the establishment and maintenance of this gradient, 
and therefore keratinocyte differentiation.  
Cx43 has been highly characterized in many tissues including the skin due to its nearly 
ubiquitous expression and implication in human diseases (Laird, 2008). Cx43 is expressed in 
dermal fibroblasts as well as the keratinocytes of the stratum basale, spinosum, and 
granulosum (Churko and Laird, 2013). However, approximately 10% of basal cells do not 
express Cx43 and these are thought to resemble stem cells (Matic et al., 2002). Both Cx26 and 
Cx30 are expressed at low levels in the stratum granulosum and minimally in the stratum 
spinosum (Scott et al., 2012; Wiszniewski et al., 2000). Currently, the roles of Cx26 and Cx30 
are not well understood in the skin but some studies have revealed Cx26 may influence 
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keratinocyte differentiation and/or proliferation (Djalilian et al., 2006; Lucke et al., 1999; 
Maher et al., 2005). However, researchers are uncovering the importance of connexins in skin 
health and wound healing as 11 inheritable skin diseases are correlated with mutations in 5 
distinct connexin genes (Lilly et al., 2016).  
1.1.4 Cutaneous Wound Healing 
In the case of injury, the skin repairs itself through a highly dynamic process in which key 
events spatially and temporally overlap (Martin, 1997; Reinke and Sorg, 2012). Immediately 
following an injurious breach of the skin barrier, damaged blood vessels vasoconstrict to 
prevent excessive blood loss while thrombogenesis initiates the generation of a protective clot 
that plugs the exposed wound (Reinke and Sorg, 2012). Along with the release of cytokines 
from platelets, local blood vessels dilate to recruit immune cells to clean up debris and 
opportunistic pathogens (Martin, 1997). Damaged keratinocytes, endothelial cells, and 
invading immune cells secrete growth factors to initiate fibroblast proliferation and 
angiogenesis which infiltrates the thrombus to generate a dense granulation tissue composed 
of fibroblasts, thick collagen bundles, immune cells, and a dense capillary network (Martin, 
1997). Growth factors also stimulate wound edge keratinocytes to adopt migratory behaviour 
wherein they crawl along the underside of the granulation tissue, while keratinocytes behind 
wound margins become highly proliferative to aid in re-epithelialization (Martin, 1997). Upon 
re-epithelialization, keratinocytes differentiate to re-establish the functional epidermal layers 
as cells in the granulation tissue undergo apoptosis until the entire tissue and clot are lost 
(Reinke and Sorg, 2012). The time required for complete epidermal re-establishment 
following wounding can vary greatly depending on the severity and type of wound, the age of 
the individual, and the presence of infection (Martin, 1997). Notably, diabetics display poor 
wound healing capabilities and often develop chronic non-healing wounds (Lim et al., 2015). 
While this context is undoubtedly multi-factorial, some suggest that a deregulation of 
epidermal connexins contributes to impaired healing in diabetics (Wang et al., 2007a). In 
additional, chronic venous leg ulcers have repeatedly demonstrated chronically upregulated 
Cx26, Cx30, and Cx43, suggesting that dynamic connexin regulation is necessary for proper 
wound healing (Brandner et al., 2004; Ghatnekar et al., 2015; Mendoza-Naranjo et al., 2012; 
Sutcliffe et al., 2015). 
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1.1.5 Connexins Involved in Cutaneous Wound Healing 
It has been found that during normal wound healing, extensive gap junction remodeling occurs 
(Becker et al., 2012; Churko and Laird, 2013). Several studies have shown a dramatic decrease 
in the expression of Cx43 in keratinocytes surrounding the wound site at the onset of healing 
(Brandner et al., 2004; Goliger and Paul, 1995; Kretz et al., 2003; Lampe et al., 1998). 
Furthermore, reducing Cx43 expression has been shown to improve keratinocyte proliferation 
and migration, limit inflammation and scaring, and promote overall beneficial wound healing 
outcomes (Churko et al., 2012; Ghatnekar et al., 2015; Mori et al., 2006; Qiu et al., 2003). On 
the other hand, both Cx26 and Cx30, which are normally located in the stratum granulosum, 
are expressed at high levels throughout all layers of the epidermis surrounding the wound site 
early in healing (Coutinho et al., 2003; Davis et al., 2013; Djalilian et al., 2006; Goliger and 
Paul, 1995; Kretz et al., 2003; Lemaitre et al., 2006). Down-regulation of these connexins later 
in the healing process is normal and may be necessary for later stages of healing (Brandner et 
al., 2004; Djalilian et al., 2006). Shortly after wounding, keratinocyte hyperproliferation 
results in epidermal thickening (Martin, 1997), and since numerous gain of function Cx26 and 
Cx30 mutants lead to hyperproliferative skin diseases (Xu and Nicholson, 2013), it is possible 
these connexins may promote a proliferative burst to jump start wound healing. However, little 
is known as to what roles Cx26 and Cx30 play in maintaining healthy epidermis. Furthermore, 
although their remodeling has been demonstrated during wound healing, it is unknown 
whether Cx26 and Cx30 gene mutations alter wound healing properties.  
1.1.6 GJB2 Mutations Involved in Skin Disease 
Cx26 is encoded by the GJB2 gene and is becoming a highly characterized member of the 
connexin family. To date, well over 100 distinct GJB2 mutations have been reported in 
patients with skin disease and/or hearing loss (Connexin-deafness homepage) (Laird, 2006; 
Lilly et al., 2016; Xu and Nicholson, 2013). Refer to Fig. 1.2 for an extensive depiction of 
these mutants on the Cx26 polypeptide. Six distinct skin diseases are specifically linked to 
GJB2 mutations that present with focal, or generalized skin abnormalities and often feature 
keratoderma (thickening of the epidermis) (Lilly et al., 2016). For example, Keratitis-
Ichthyosis-Deafness Syndrome (KIDS), Bart-Pumphrey Syndrome and Vohwinkel  
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Figure 1.2 
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Figure 1.2. Composite diagram of reported disease-linked Cx26 mutants. 
The Cx26 polypeptide sequence highlighting the location of numerous disease-linked mutants. 
Spanning every domain of the Cx26 protein, over 100 distinct Cx26 mutants (not all shown) 
are linked to non-syndromic hearing loss (green circles) and syndromic skin disease (red 
circles). 
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Syndrome, stem from GJB2 mutations and are characterized as diffuse, hyperproliferative skin 
diseases, whereas palmoplantar keratoderma with deafness can present with focal keratoderma 
on volar skin (Avshalumova et al., 2014). A GJB2 gene mutation however, may lead to skin 
disease, hearing impairments, or both, and some mutations lead to more profound disease than 
others (Lee and White, 2009). For example, in KIDS alone, the G45E Cx26 mutant leads to 
an infant-lethal form (Koppelhus et al., 2011), while a milder form is caused by the N14K 
mutant (Lazic et al., 2008). Numerous mutants affecting the NT (amino acids, 1-20) and EL1 
(amino acids 41-75) domains are known to form leaky hemichannels (G11R, G12R, N14K, 
N14Y, S17F, A40V, G45E, D50A, D50N) and are linked to syndromic pathologies displaying 
severe skin disease and hearing impairments (Garcia et al., 2016a). Interestingly, the S17F 
Cx26 mutant has been reported to bind with Cx43, a non-traditional binding partner, and form 
leaky heteromeric hemichannels (Garcia et al., 2015). The connection between leaky 
hemichannels and syndromic disease suggests they may contribute to both skin disease and 
hearing loss in patients. Studies have also shown that some GJB2 mutations render non-
functional Cx26 gap junctions but do not confer any form of skin disease, likely due to 
compensation from other connexins in the epidermis (Scott et al., 2012). A possible reason for 
these differences among disease potential could be due to certain mutations acting in a trans-
dominant manner by affecting other connexins. While many mutations have been identified, 
it is not fully understood how and which mutant connexins interact with other connexins, 
modify channel properties, and finally disrupt tissue homeostasis.  
1.1.7 GJB6 Mutations Involved in Skin Disease 
Cx30 is encoded by the GJB6 gene and has received less investigative attention than 
Cx26 and Cx43. Currently, five mutations are linked to syndromic skin diseases (Clouston 
Syndrome, KIDS, and Vohwinkel Syndrome) and two are linked to non-syndromic hearing 
loss (Fig.1.3). Clouston Syndrome is a rare condition characterized by varying severities of 
palmoplantar keratoderma, alopecia, and nail dystrophy (Lamartine et al., 2000) and is 
prevalent among the French-Canadian population due to a founder effect (Kibar et al., 2000). 
Some mutations leading to skin disease have been shown to induce cell death pathways in 
vitro (V37E and A88V) (Berger et al., 2014), while others display trafficking defects (G11R 
and G59R) (Essenfelder et al., 2004; Nemoto-Hasebe et al., 2009). Furthermore, G11R and  
!!
12!
 
Figure 1.3 
 
 
 
 
 
 
 
 
!!
13!
Figure 1.3. Composite diagram of reported disease-linked Cx30 mutants. 
The Cx30 polypeptide sequence highlighting the location of disease-linked mutants. T5M and 
A40V are the only mutants linked to non-syndromic hearing loss (green circles), whereas the 
5 other mutants are associated with syndromic skin diseases (red circles). 
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A88V Cx30 may form leaky hemichannels that increase purinergic signaling and deregulate 
keratinocyte proliferation/differentiation (Berger et al., 2014; Essenfelder et al., 2004). 
Despite these observations, it is still poorly understood how Cx30 contributes to overall skin 
integrity. However, relative to Cx26, the lack of Cx30 mutations linked to hearing loss and 
skin disease predicts that Cx30 may have a smaller contribution to auditory and epidermal 
physiology. 
1.1.8 Modeling Connexin-Linked Skin Disease 
While cellular based experiments are useful for understanding certain aspects of gap 
junction function or malfunction, animal based models are superior for understanding the role 
of connexins in the skin as a complete tissue. Numerous researchers have employed rodent 
models to study connexins in the skin and also to investigated their effects on wound healing 
(Bakirtzis et al., 2003; Bosen et al., 2014; Churko et al., 2011a; Djalilian et al., 2006; Schutz 
et al., 2011; Wang et al., 2007a). Several of these models express connexin mutants to 
genetically mirror human connexin-linked skin diseases. For example, the G60S Cx43 mouse 
represents human oculodentodigital dysplasia (Churko et al., 2011a), the conditional D66H 
Cx26 mouse represents true Vohwinkel Syndrome (Bakirtzis et al., 2003), the F137L Cx31 
mouse represents erythrokeratoderma variabilis (Schnichels et al., 2007), and as I will discuss, 
the S17F Cx26 and A88V Cx30 mice represent human KIDS, and Clouston Syndrome, 
respectively (Bosen et al., 2014; Schutz et al., 2011). Additionally, numerous studies, 
including previous work from our lab (Churko et al., 2012; Churko et al., 2010; Churko et al., 
2011b; Langlois et al., 2007; Maher et al., 2005), have generated a greater understanding of 
the role of Cx43 in the epidermis, its effects on wound healing, and how certain mutations 
impact skin health. Some researchers have repeatedly demonstrated the benefits of Cx43 
inhibition during healing (Coutinho et al., 2005; Ghatnekar et al., 2015; Grek et al., 2015; 
Grupcheva et al., 2012; Qiu et al., 2003) and even started companies to develop and 
commercialize Cx43-targetted wound therapies (Colin Green and David Becker – CoDa 
Therapeutics; Gautnam Ghatnekar – FirstString Research). There is, however, only one Cx26 
mouse model that has been used to assess the influence of Cx26 on wound healing, which has 
proposed a role for Cx26 during wound inflammation and epidermal remodeling (Djalilian et 
al., 2006). Despite this, and the evidence suggesting Cx26 and Cx30 are dynamically regulated 
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during proper wound healing, there remains insufficient animal models to investigate their 
impact and potential therapeutic value towards wound healing. 
Recently, a group from Germany lead by Klaus Willecke has generated two disease-linked 
mutant mouse strains that are suitable models of human KIDS and Clouston Syndrome: the 
Cx26S17F/+ mouse and Cx30A88V/+ mouse, respectively (Bosen et al., 2014; Schutz et al., 2011). 
As described in this thesis, our laboratory has generated a tissue specific S17F Cx26 mouse 
(Cx26K14-S17F/+) in which the mutant connexin was expressed solely in tissues expressing 
keratin 14 (K14). Cre-recombinase insertion of the mutant gene only occurred in tissues 
expressing K14 and resulted in selective expression of S17F Cx26 in basal cells of the 
epidermis and a few other stratified epithelial tissues, while under the expression of the 
endogenous Cx26 promoter. This allowed us to study the effect of the S17F Cx26 mutant on 
the epidermis with presumably far less complications from its expression in other tissues such 
as the liver, kidney, intestine, placenta, mammary gland, and brain (Filippov et al., 2003; 
McLachlan et al., 2007). In addition, we have obtained the A88V Cx30 mutant mice 
(Cx30A88V/+ and Cx30A88V/A88V) from the Willecke laboratory. Together, we will use these 
mice to gain insight into the physiological and pathological mechanisms in which connexins 
and connexin mutants affect epidermal homeostasis and wound healing. The importance of 
using disease-relevant mouse models lies in the genetic consistency that reference cell 
experiments cannot recapitulate. These mice have the correct ratio of mutant to wild-type 
alleles; something that is very difficult to reliably attain in cellular transfection-based 
experiments. This gives us the advantage of being able to use mutant mice to culture primary 
keratinocytes for in vitro experiments, while the genetic dosage of the mutant alleles mirrors 
that of the human disease. Lastly, these mice allowed us to examine the temporal and spatial 
localization of mutant connexins within intact murine epidermis while establishing a platform 
to perform wound healing experiments.  
1.1.9 Hypothesis 
We hypothesized that disease-linked Cx26 and Cx30 mutants disrupt epidermal homeostasis 
and wound healing through modification of keratinocyte proliferation, differentiation, and 
migration. To test this hypothesis, we expressed five Cx26 mutants (N14K, D50N, N54K, 
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M163V, S183F) in reference cells and keratinocytes to evaluate their cellular characteristics. 
For each mutant, we investigated their ability to traffic, form gap junction channels, plasma 
membrane hemichannels, and to exhibit trans-dominant effects on Cx30 and Cx43, as well as 
the ability to induce cell death. We further modeled connexin-linked skin diseases using a 
tissue-specific S17F Cx26 mutant mouse, and a global A88V Cx30 mutant mouse. The foot 
pad skin of these mice were assessed to investigate the effect of the mutants on keratinocyte 
differentiation, proliferation, and skin morphology. Primary keratinocytes were isolated from 
these mice to assess connexin localization, overall GJIC competency, and collective cell 
migration. Finally, wound healing was assessed in these mice using a standard dorsal skin 
punch biopsy. The goal of these investigations was to determine the effect of Cx26 and Cx30 
mutants on the epidermis and wound healing, and to shed light on the role of Cx26 and Cx30 
in normal healthy skin.  
1.1.10 Objectives 
The specific objectives for this study were to:  
1. Characterize the skin phenotype in mice harbouring Cx26 and Cx30 mutants. 
 
2. Examine the consequences of keratinocytes harbouring connexin mutants in primary 
mouse cultures and cells engineered to express Cx26 mutants. 
 
3. Assess epidermal wound closure and remodeling in response to wounding in mutant 
mice and littermate controls. 
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Chapter 2 
 
Induction of cell death and gain-of-function properties of Cx26 
mutants predict the severity of diseases linked to GJB2 mutations 
 
Here we investigated five autosomal dominant Cx26 mutants (N14K, D50N, N54K, M163V, 
S183F) that are linked to various syndromic or non-syndromic diseases to uncover the 
molecular mechanisms underpinning their link to disease.  We demonstrated that when the 
N14K and D50N mutants were expressed in gap junction-deficient HeLa cells, cells were 
triggered into a cell death pathway. The N54K mutant was retained primarily within 
intracellular compartments and displayed trans-dominant properties on coexpressed Cx30 and 
Cx43. The S183F mutant formed some gap junction plaques but was largely retained within 
the cell and exhibited only a mild trans-dominant reduction in gap junctional intercellular 
communication when co-expressed with Cx30. The M163V mutant which causes hearing loss 
alone exhibited impaired gap junction function and showed no trans-dominant interactions. 
Taken together, we suggest that Cx26 mutants that promote cell death or cause reductions in 
the functions of connexins co-expressed in keratinocytes will lead to skin diseases and hearing 
loss while mutants that have reduced channel function but exhibit no aberrant effects on co-
expressed connexins cause only hearing loss. Moreover, GJB2 mutations that cause cell death 
lead to more severe syndromic disease.   
A version of this chapter will be submitted for publication by the end of the month. 
Authors: Eric R. Press, John J. Kelly, Katrina Chin, Anton Alaga, Qing Shao, and Dale W. 
Laird 
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2.1  Introduction 
The GJB2 gene encoding connexin26 (Cx26) has an estimated mutation prevalence of 3% in 
the general population (Chan and Chang, 2014). Globally, an estimated 17.3% of hearing loss 
cases are linked to bi-allelic GJB2 mutations highlighting the importance of Cx26 in hearing 
(Chan and Chang, 2014). In addition, numerous syndromic diseases exhibiting hearing deficits 
and a variety of skin abnormalities are linked to GJB2 missense mutations with autosomal 
dominant inheritance (Avshalumova et al., 2014). Interestingly, some speculate the 
pervasiveness of GJB2 mutations may result from a selective heterozygote advantage (Chan 
and Chang, 2014) conferred by sub-clinical epidermal thickening and a stronger cutaneous 
barrier (D'Adamo et al., 2009). In humans, Cx26 is expressed in a variety of tissues and not 
surprisingly, in several cell types within the cochlea (Jagger and Forge, 2015) and in 
keratinocytes of the epidermis (Scott et al., 2012). Within these tissues, several other members 
of the connexin family are expressed, most notably Cx30 and Cx43, wherein mutations in their 
genes have also been implicated in syndromic diseases sharing some similar features 
(Avshalumova et al., 2014; Martin et al., 2014; Scott et al., 2012).  
Cx26 is a gap junction protein that oligomerizes in the cell to form hexameric transmembrane 
channels called connexons (Laird, 2006). Connexons that span the plasma membrane are 
called hemichannels and may allow a cell to pass small signalling molecules between the 
cytosol and the extracellular environment (Laird, 2006). However, when hemichannels from 
adjacent cells dock together, they form a single conduit called a gap junction channel which 
connects the cytosol of these cells and facilitates gap junctional intercellular communication 
(GJIC) (Laird, 2006). ATP, IP3, and cations frequently pass through Cx26 gap junction 
channels and have been shown to play important roles in regulating cell proliferation and 
differentiation as well as maintaining ionic homeostasis within tissues. (Alexander and 
Goldberg, 2003; Djalilian et al., 2006). 
The Cx26 polypeptide chain has four transmembrane domains, two extracellular loops, an 
intracellular loop, and cytosolic N- and C- termini. The N-terminal domain (amino acid 
residues 1-20) is suggested to play a major role in voltage sensing and channel gating (Maeda 
et al., 2009). The extracellular loops (E1 and E2) (amino acid residues 41-75 and 155-192, 
respectively) are thought to be key domains for oligomerization and inter-channel docking 
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(Maeda et al., 2009). Disease-causing point mutations have been documented to affect every 
domain of the Cx26 polypeptide, and depending on the mutation and the motif that harbors 
the altered residue, variations can occur in connexin folding and trafficking, channel assembly, 
channel gating, half-life, degradation, and/or interactions between other co-expressed 
connexins (Laird, 2006). Some mutants have been shown to disrupt several connexin life-
cycle characteristics (Garcia et al., 2015) increasing the complexity of delineating how GJB2 
gene mutations can cause diseases that affect one or more organs and vary in severity.  
In this study we selected 5 autosomal dominant GJB2 missense mutations that result in single 
amino acid substitutions in various domains of the Cx26 polypeptide and are linked to an array 
of auditory and skin pathologies. The N14K mutant causes a disease that shares symptoms 
with Clouston Syndrome and KIDS (Lazic et al., 2008), the D50N mutant leads to KIDS 
(Mazereeuw-Hautier et al., 2007), the N54K mutant results in Bart-Pumphrey syndrome 
(Richard et al., 2004), and the S183F mutant causes palmoplantar keratoderma and hearing 
loss (de Zwart-Storm et al., 2008b). Finally, the M163V mutant is linked to moderate hearing 
loss only (Marlin et al., 2001). Considering the pleiotropic nature of the Cx26 mutants, we 
proposed that mutants which give rise to similar clinical presentations would share common 
mechanisms of action.  
Here we found that the N14K and D50N mutants leading to wide spread erythrokeratoderma 
and severe hearing loss caused cell death, the N54K and S183F mutants leading to 
palmoplantar keratoderma and hearing loss had trafficking defects and reduced channel 
function, and the M183V mutant leading to hearing loss alone had reduced channel function. 
Lastly, all mutants linked to syndromic disease had trans-dominant effects on co-expressed 
connexins. 
 
2.2  Materials and Methods 
2.2.1  Cell Culture 
Connexin-deficient cervical cancer cells (HeLa) as described in (Elfgang et al., 1995) were 
purchased from ATCC and Rat Epidermal Keratinocytes (REKs) originally characterized in 
(Baden and Kubilus, 1983) were generously provided by Dr. Vincent Hascall. All cells were 
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grown in DMEM (Life Technologies Cat# 11965-092) supplemented with fetal bovine serum, 
2 mM L-glutamine (Life Technologies Cat# 25030-081), penicillin and streptomycin 
according to (Penuela et al., 2007). 
2.2.2 cDNA Constructs and Transfections 
cDNA encoding human Cx26 was provided by Dr. C. G. Naus (University of British 
Columbia, Vancouver, BC, Canada). PCR was used to add XhoI and EcoRI restriction sites 
to the 5′ and 3′ ends of Cx26 and the resulting cDNAs were cloned into the pEGFP-N1 vector 
(BD Biosciences Clontech) and sequenced for verification with a 17-amino-acid linker 
sequence separating the Cx26 and GFP moieties. Constructs encoding human N14K, D50N, 
N54K, M163V, and S183F Cx26-GFP were further obtained from NorClone by using a 
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) in accordance with the 
manufacturer's instructions. RFP-tagged Cx30 and Cx26 constructs were previously described 
(Berger et al., 2014). All constructs were validated by sequencing. GFP and RFP tags were 
shown not to dramatically affect connexin trafficking or protein function as previously shown 
(Thomas et al., 2005). Cells at ~60% confluency in 35 mm dishes were transiently transfected 
using Lipofectamine 2000. Transfection mixtures contained 200 µl of Opti-MEM Reduced 
Serum Medium (Life Technologies Cat# 31985-070), 1 µl of LF2000 transfection reagent 
(Invitrogen Cat# 11668019), and 1 µg of GFP-tagged Cx26, N14K, D50N, N54K, M163V, or 
S183F cDNA constructs. For co-expression experiments, transfection mixtures differed in that 
0.5 µg of GFP-tagged constructs plus 0.5 µg of RFP-tagged Cx26 or Cx30 were added to 
produce roughly equal expression of mutant to WT connexins. The mixture was gently 
swirled, incubated at room temperature for 10 minutes, and added drop-wise to cells growing 
in DMEM. All cells were used for experiments between 24-48 hours following transfection. 
2.2.3 Immunofluorescent labeling 
HeLa cells or REKs grown to ~80% confluency on sterile glass coverslips, were washed with 
phosphate-buffered saline (PBS), and fixed in an ice-cold solution of 80% methanol and 20% 
acetone for 10 minutes. Coverslips were then washed in PBS, blocked in a 2% bovine serum 
albumin (BSA) solution (diluted in PBS) for 30 minutes then incubated at room temperature 
for 1 hour with the following primary antibodies diluted in BSA solution: 1/500 mouse anti-
protein disulfide isomerase (PDI) (Assay Designs Cat# SPA-891) or 1/500 rabbit anti-Cx43 
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(Sigma-Aldrich Cat# C6219) or 1/200 rabbit anti-cleaved caspase 3 (Sigma-Aldrich Cat# 
C8487). Secondary antibodies 1/500 Alexa-488-conjugated anti-mouse (Invitrogen: Cat# 
A11017) and 1/500 Alexa-555-conjugated anti-rabbit (Invitrogen Cat#A21429) were used to 
detect primary antibodies. Cells were then incubated for 10 minutes at room temperature with 
Hoechst 33342 (1/1000 diluted in ddH20) (Molecular Probes Cat# H3570), mounted with 
Airvol (containing 15% polyvinyl alcohol, 33% glycerin, and 0.1% sodium azide), and imaged 
with a Zeiss LSM 800 confocal Airyscan microscope equipped with ZenWorks software. 
Images were captured with a 63x oil immersion objective. Gap junction plaques between 
REKs were quantified in a blinded fashion by counting the number of green and red punctae 
at individual cell-cell interfaces. A minimum of 24 separate images were captured for each 
mutant and a one-way ANOVA was performed on the means of 3 biological replicates. 
2.2.4 Dye Transfer Studies  
HeLa cells or REKs grown to ~60% confluency and engineered to express GFP-tagged Cx26 
or Cx26 mutants (and RFP-tagged connexins for co-expression experiments) as described 
above were microinjected with Alexa-Fluor-350 (410 Da, Molecular Probes Cat# A10439) to 
assess gap junction dye transfer previously described (Huang et al., 2013). Briefly, cells were 
microinjected using a fine glass needle attached to an Eppendorf FemtoJet automated 
microinjector. Cells were imaged using a Leica DM IRE2 epifluorescent microscope to 
visualize GFP and RFP, then one minute following microinjection, they were imaged again to 
visualize the spread of Alexa-Flor-350. All images were captured with a 20x objective. The 
incidence of dye transfer within each trial was quantified as the percent of microinjected cells 
that passed dye to neighbouring cells and a one-way ANOVA was performed on the means of 
at least 3 replicates. Tukey’s post-hoc test compared the means of each condition to the 
condition in which cells expressed GFP-tagged WT Cx26. Untransfected HeLa cells were used 
as negative controls and HeLa cells expressing Cx26-GFP only, or in addition to Cx26-RFP 
or Cx30-RFP served as positive controls for all dye transfer experiments in HeLa cells. Lastly, 
for dye transfer experiments in REKs, untransfected REKs, or REKs expressing Cx26-GFP 
were used as positive controls.  
2.2.5 Hemichannel Assay 
HeLa cells were seeded at low density to isolate cells from one another and then were 
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engineered to express Cx26 or Cx26 mutants as described above. Propidium iodide (PI) dye 
uptake assays to assess hemichannel activity were performed as noted in (Berger et al., 2014). 
Briefly, cells were washed in extracellular solution (ECS) (142 mM NaCl, 5.4 mM KCl, 1.4 
mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 25 mM D-glucose, osmolarity 298 mOsm, pH 
adjusted to 7.35 using NaOH) and then twice in either ECS or divalent cation free solution 
(DCF-ECS) (same as ECS but with Ca2+ and Mg2+ substituted for 2 mM EGTA). ECS or DCF-
ECS containing 1 mg/ml PI (668.4 Da, Invitrogen) was added to the cells and incubated at 
37˚C for 15 minutes. Cells were washed 3 times with ECS, then ~40 isolated cells per replicate 
were imaged to visualize GFP and PI using the Leica microscope and OpenLab software. For 
each replicate, the number of cells containing PI was recorded as a percentage of the total 
number of GFP-positive cells and a two-way ANOVA was performed on the means of at least 
3 replicates. Sidak’s post-hoc test compared the means of ECS and DCF-ECF conditions.  
2.2.6 Statistical Analysis 
Graph Pad Prism version 6 was used for all statistical analysis and statistical significance was 
noted when p<0.05. All histogram values represent the mean + SEM. 
 
2.3 Results 
2.3.1 N14K and D50N mutants induce cell death in vitro  
In order to assess the impact of Cx26 mutants on cellular health, specific Cx26 mutants were 
expressed in GJIC-deficient HeLa cells. HeLa cells expressing the N14K and D50N mutants 
displayed pyknotic nuclei and blebbing as early as 24 hours post transfection, therefore we 
immunolabelled cleaved caspase 3 (CC3) to determine if cells expressing these mutants were 
undergoing apoptosis (Fig 2.1A). HeLa cells expressing the GFP-tagged N14K and D50N 
mutants displayed a high degree of CC3 immunolabeling (Fig. 2.1B), similar to cells treated 
with staurosporine, suggesting that the expression of these mutants in HeLa cells triggers 
apoptosis in vitro. Consequently, cell expressing the N14K or D50N mutants were deemed 
not suitable for further mutant localization or functional studies.  
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Figure 2.1 
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Fig. 2.1. N14K and D50N Cx26 mutants linked to KIDS induce cell death. (A) HeLa cells 
expressing GFP-tagged Cx26, N14K, and D50N mutants (green) were immunolabelled to 
highlight cleaved-caspase-3 (red) indicating cells undergoing apoptosis and nuclei were 
stained with Hoechst (blue). Cells treated for 2 hours with 1µM staurosporine were used as a 
positive control for apoptotic cells. (B) Cells expressing N14K and D50N mutants were often 
apoptotic compared to Cx26 expressing cells ****p<0.0001, N=3 separate experiments. Scale 
bar = 40µm. 
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2.3.2 N54K and S183F mutants have trafficking defects and impaired dye-
transfer ability 
Cx26 mutants associated with hearing loss and various skin diseases were expressed in HeLa 
cells to examine how a substituted amino acid in Cx26 may affect its trafficking, cellular 
localization, or gap junction function. Cx26 and the M163V mutant formed abundant gap 
junction plaques at cell-cell interfaces (Fig. 2.2A). The S183F mutant was retained primarily 
in intracellular compartments but formed a small number of gap junction plaques while the 
N54K mutant colocalized extensively with PDI labelling of the endoplasmic reticulum (ER) 
(Fig. 2.2A). The ability of the disease-linked mutants to form functional gap junction channels 
was assessed by quantifying intercellular transfer of microinjected Alexa-Fluor-350 in HeLa 
cells expressing Cx26 or the various mutants. Paired cells expressing Cx26 had nearly 100% 
incidence of dye transfer (Fig. 2.2B) while cells expressing the M163V mutant passed dye 
approximately 40% of the time. Cells expressing either the N54K or S183F mutants were 
essentially unable to establishing gap junction channels capable of dye transfer similar to 
controls (Fig. 2.2B).  
2.3.3 Cx26 mutants exhibit dominant-negative effects on Cx26 function.  
To assess the distribution and function of Cx26 mutants under physiological conditions where 
both wild type and mutant Cx26 are expressed in the same cell, we engineered HeLa cells to 
express RFP-tagged Cx26 and GFP-tagged Cx26 mutants at approximately a 1:1 ratio. Cx26 
and the M163V mutant formed numerous gap junction plaques at the cell surface and were 
highly colocalized (Fig. 2.3A). Surprisingly, the N54K mutant was able to traffic to the cell 
surface and form intermixed gap junction plaques when co-expressed with Cx26 (Fig. 2.3A). 
The S183F mutant remained distributed in intracellular compartments, however was also 
found in several plaques when co-expressed with Cx26 (Fig. 2.3A). These findings suggest 
that all mutants were more readily assembled into a gap junction plaque when co-expressed 
with Cx26. To further examine the interaction between the Cx26 mutants and wild-type Cx26, 
we quantified Alexa-Fluor-350 dye-transfer between HeLa cells that coexpressed the mutants 
and Cx26 (Fig 2.3B). Cells expressing M163V and S183F mutants reduced the overall 
functional gap junctional status of Cx26. However, the N54K mutant abolished the functional 
gap junctional status of co-expressed Cx26 as assessed by the ability to pass a fluorescent dye. 
(Fig 2.3B).  
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Figure 2.2 
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Fig. 2.2. Cx26 mutants linked to skin disease are frequently localized to intracellular 
compartments and have limited dye transfer capability. (A) HeLa cells expressing GFP-
tagged Cx26, N54K, M163V, or S183F mutants (green) were immunolabeled for protein 
disulfide isomerase (PDI, red), a resident protein of the endoplasmic reticulum, and stained 
with Hoechst (blue) to denote the nuclei. Cx26 and the M163V mutant form numerous gap 
junction plaques at cell interfaces (arrows). N54K and S183F mutants were mostly located 
within the cell while the S183F mutant formed a few gap junction plaques. (B) Alexa-Fluor-
350 dye transfer in pairs or clusters of HeLa cells expressing N54K and S183F mutants was 
negligible whereas ~ 40% of the cells expressing the M163V mutant transferred dye (C). 
Example images of dye-transfer experiments showing successful (Cx26) and unsuccessful 
dye-transfer (N54K). **p<0.01, ****p<0.0001, N = 3 separate experiments. The number of 
cells that were microinjected to test for dye transfer in each case is noted in (B). Ctrl represents 
untransfected HeLa cells. Scale bar in (A, C) = 20µm. 
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Figure 2.3 
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Fig. 2.3. Cx26 mutants exhibit dominant-negative properties on Cx26 in HeLa cells. (A) 
HeLa cells expressing GFP-tagged Cx26 or N54K, M163V, and S183F mutants (green) 
together with Cx26-RFP (red) were stained with Hoechst (blue). All mutants formed gap 
junction plaques at cell interfaces (arrows) and colocalized with Cx26-RFP. (B) Untransfected 
control cells (Ctrl), or cells expressing the N54K mutant together with Cx26 failed to pass 
microinjected Alexa-350 dye. Cells expressing S183F and M163F mutants together with 
Cx26-RFP had reduced incidences of dye transfer compared to cells expressing Cx26-GFP. 
****p<0.0001, N = 3 separate experiments. The number of cells that were microinjected is 
noted in (B). Scale bar = 20µm. 
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2.3.4 N54K and S183F mutants display trans-dominant effects on Cx30 
Since Cx26 and Cx30 are co-expressed in the same keratinocytes as well as several cell types 
of the inner ear (Jagger and Forge, 2015), we engineered HeLa cells to express RFP-tagged 
Cx30 and GFP-tagged Cx26 mutants to assess potential trans-dominant interactions. Cx26 as 
well as the M163V and S183F mutants were able to form gap junction plaques at the cell 
surface and often colocalized with Cx30 (Fig. 2.4A). The N54K mutant formed very few 
plaques and remained in an ER-like distribution pattern but also appeared to impair the ability 
of Cx30 to form abundant gap junction plaques indicating a trans-dominant effect on Cx30 
trafficking (Fig. 2.4A). Next we determined if the Cx26 mutants exhibited a trans-dominant 
effects on Cx30 channel function using Alexa-Fluor-350 dye-transfer studies (Fig. 2.4B). 
Microinjected HeLa cells expressing Cx30 alone, or co-expressing Cx30 and Cx26 had nearly 
100% incidence of dye-transfer. However, cells coexpressing Cx30 and either the N54K or 
S183F mutants had significantly reduced ability to pass dye indicating that these mutants had 
a trans-dominant effect on Cx30 channel function. Interestingly, the M163V mutant did not 
significantly reduce the ability of Cx30 positive cells to pass dye.  
2.3.5 N54K displays mild trans-dominant effect on endogenous Cx43 
To assess the impact of Cx26 mutants in a more tissue-relevant cell, we engineered REKs to 
express Cx26 mutants and determined their potential for trans-dominant effects on 
endogenous Cx43. The N54K mutant formed fewer gap junction plaques than Cx26 and 
remained mostly intracellular (Fig. 2.5A, B). The M163V and S183F mutants formed 
numerous gap junction plaques although the S183F mutant was found in a typical ER-like 
distribution pattern (Fig. 2.5A). None of the Cx26 mutants appeared to impair Cx43 gap 
junction plaque formation (Fig. 2.5B). REKs engineered to express Cx26 mutants were 
microinjected with Alex-Fluor-350 which readily passes through both Cx26 and Cx43 gap 
junction channels.  Only cells expressing the N54K mutant exhibited a significant decrease in 
dye transfer suggesting that the N54K mutant had a modest trans-dominant-negative effect on 
endogenous Cx43. (Fig. 2.5C).  
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Figure 2.4 
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Fig. 2.4. Cx26 mutants linked to syndromic disease exhibit trans-dominant properties on 
Cx30 in HeLa cells. (A) HeLa cells expressing GFP-tagged Cx26, N54K, M163V, and S183F 
mutants (green) and RFP-tagged Cx30 (red) were stained with Hoechst (blue). S183F and 
M163V mutants formed abundant gap junction plaques at cell interfaces (arrows) and 
colocalized with Cx30, while S183F mutants were also located within the cell. N54K mutants 
remained mostly within the cell although they formed a few gap junction plaques (arrows) and 
impaired the ability of Cx30 to assemble gap junctions at the cell surface. (B) Cells expressing 
the M163V mutant together with Cx30 had dye transfer abilities similar to cells expressing 
Cx26 and Cx30, or Cx30 alone, whereas the incidences of dye transfer in cells expressing the 
N54K and S183F mutants together with Cx30 was markedly reduced. ****p<0.0001, N ≥ 3 
separate experiments. The number of cells that were microinjected in each situation is noted 
in (B). Scale bar = 20µm. 
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Figure 2.5 
!!
42!
Fig. 2.5. The N54K mutant exhibits trans-dominant inhibition of endogenous Cx43 in 
REKs. (A) REKs expressing GFP-tagged Cx26, N54K, M163V, and S183F mutants (green) 
with endogenous Cx43 immunolabelled in red were stained with Hoechst (blue). The N54K 
and S183F mutants were inefficient at forming gap junction plaques and were often found 
intracellular. The M163V mutant formed abundant GJ plaques similar to Cx26. (B) The N54K 
mutant formed fewer gap junction plaques compared to Cx26, however endogenous Cx43 gap 
junction formation was not impaired by any of the mutants. (C) REKs expressing the N54K 
mutant had reduced dye transfer capabilities compared to untransfected REKs (Ctrl), and 
REKs expressing Cx26. **p>0.01, n ≥ 24 individual images. The number of cells 
microinjected is noted in (C). Scale bar = 20µm. 
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2.3.6 N54K and S183F mutants display reduced hemichannel function 
Aside from GJIC and trafficking defects, mutant connexins may further disrupt hemichannel 
properties. We therefore used a propidium iodide (PI) dye uptake assay to assess the function 
of mutant hemichannels in normal extracellular solution (ECS) and divalent-cation-free ECS 
(DCF-ECS) which stimulates hemichannels to open (Fasciani et al., 2013). All mutant 
expressing cells displayed minimal PI uptake in ECS conditions, and similar to Cx26, the 
M163V mutant exhibited nearly 100% incidence of PI uptake in DCF-ECS, indicating fully 
functional hemichannel activity (Fig. 2.6B). Interestingly, in DCF-ECS, cells expressing the 
N54K mutant demonstrated approximately 60% incidence of PI uptake suggesting moderately 
functional hemichannel formation, while cells expressing the S183F mutant displayed no 
increase in PI uptake, indicating non-functional hemichannel formation (Fig. 2.6B). 
 
2.4 Discussion 
Due to a high carrier frequency of GJB2 mutations in the population and greater than 100 
disease causing Cx26 mutants now identified in humans (Lee and White, 2009; Martin and 
van Steensel, 2015; Xu and Nicholson, 2013), understanding how distinct GJB2 mutations 
cause disease is critical when considering any prospective therapies. The scope of possible 
Cx26 dysfunction is vast considering the possibility of gain- or loss-of functions of gap 
junctions, hemichannels, or additions to the connexin interactome that may present anywhere 
throughout the Cx26 life-cycle. Furthermore, the complexity of Cx26 dysfunction is 
compounded by its potential to interact with several co-expressed connexin binding partners 
in numerous different tissues including the skin and inner ear. The pleiotropic nature of Cx26-
linked diseases raises obvious questions as to how specific GJB2 gene mutations lead to 
hearing loss, or hearing loss combined with skin disorders of varying severity. Here we studied 
five autosomal dominant Cx26 mutants: four that cause hearing loss in addition to various skin 
disorders (N14K, D50N, N54K, S183F), and one that causes hearing loss alone (M163V). We 
found that the N14K and D50N mutants which cause wide spread and severe skin lesions 
overtly induced cell death, whereas the N54K and S183F mutants which cause regional and 
moderate skin lesions, had defects in connexin trafficking, as well as impaired gap junction  
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Figure 2.6 
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Fig. 2.6. Cx26 mutants linked to syndromic disease display reduced hemichannel 
function in HeLa cells. (A) Isolated HeLa cells that were engineered to express GFP-tagged 
Cx26, N54K, S183F, or M163V mutants were incubated in PI-containing ECS or DCF-ECS 
and the incidence of PI-uptake was quantified from random image fields. Image fields 
captured GFP-tagged connexins (green) and intracellular PI-uptake (red). (B) In DCF-ECS, 
cells expressing the N54K mutant displayed approximately 60% incidence of PI-uptake and 
cells expressing the S183F mutant displayed minimal PI-uptake. Cells expressing the M183V 
mutant, much like Cx26, exhibited nearly 100% incidence of PI-uptake. All mutants, except 
for S183F, demonstrated increased PI-uptake in DCF-ECS compared to control ECS 
conditions. ****p>0.0001, N=3 separate experiments. The number of image fields is noted 
below the histogram in (B). Scale bar = 50µm. 
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and hemichannel function (Fig. 2.7). In addition, the M163V mutant which causes moderate 
hearing loss alone, displayed only impaired gap junction function (Fig. 2.7) with no trans-
dominant properties on other co-expressed members of the connexin family. We also showed 
that while all mutants displayed dominant-negative properties on wild type Cx26, the 
syndromic N54K and S183F mutants trans-dominantly impaired the function of co-expressed 
Cx30 and/or Cx43 gap junctions (Fig. 2.7).  
Several extensive reviews have discussed the functional characteristics of over 60 distinct 
disease-causing Cx26 mutants that were investigated using heterologous expression models 
(Garcia et al., 2015; Lee et al., 2009; Xu and Nicholson, 2013). These reports have elucidated 
some major characteristics of disease causing mutants: a reduction or ablation of gap junction 
formation/function, altered selectivity of signaling molecules, and aberrant hemichannel 
activity. While syndromic and non-syndromic mutations affect amino acid residues in 
cytoplasmic, extracellular, and transmembrane domains, the majority of syndromic mutations 
cluster to the N-terminal and EL1 domains (Garcia et al., 2016b; Lee and White, 2009; Martin 
and van Steensel, 2015; Xu and Nicholson, 2013). Additionally, it seems that mutants which 
alter molecular selectivity lead only to non-syndromic hearing loss whereas aberrant 
hemichannels are almost exclusively associated with severe syndromic disease (Garcia et al., 
2016b; Xu and Nicholson, 2013). Recently, the S17F mutant which leads to a relatively severe 
form of KIDS, has been shown to form essentially non-functional homomeric gap junctions 
or hemichannels, yet oddly produces hyperactive heteromeric hemichannels with Cx43 
(Garcia et al., 2015). This finding further established that aberrant hemichannels are a common 
characteristic of KIDS mutants, but importantly, it demonstrated the need to carefully examine 
mutants for trans-dominant effects on co-expressed connexins – including non-traditional 
binding partners. It is important to note that a trans-dominant interaction with a non-traditional 
binding partner such as Cx43, can be considered a gain-of-function property. Therefore, we 
also explored possible trans-dominant effects on Cx30 which is co-expressed with Cx26 in the 
skin and cochlea, as well as Cx43, which is co-expressed with Cx26 in the skin and also found 
in the cochlea. Furthermore, at least eight additional mutants have been identified in patients 
that still require functional analysis (Martin and van Steensel, 2015). This report describes the 
M163V and S183F mutants which have been limitedly investigated (Bruzzone et al., 2003; 
Shuja et al., 2016), and the N54K mutant which was merely reported once in a patient with  
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Figure 2.7 
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Fig. 2.7. Modelling the cellular characteristics of autosomal dominant GJB2 mutations. 
Table of the 5 Cx26 mutants and their associated clinical features (top left). Schematic of the 
Cx26 polypeptide chain including the approximate location of each mutant included in the 
study (top right). Every subsequent square displays the localization (intracellular and/or 
membrane trafficking), channel formation and gap junction and hemichannel function (highly 
functional = double arrows, reduced function = wavy arrows, non-functional = no entry 
symbol) of each Cx26 mutant (green), and is separated into quadrants corresponding to the 
context of cells co-expressing the mutant with Cx26 (blue), Cx30 (purple), or Cx43 (red). 
Mutants linked to severe syndromic disease are watermarked in red, mutants linked to 
moderate syndromic disease are watermarked in yellow, and mutants linked to non-syndromic 
hearing loss are watermarked in green.  
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Bart-Pumphrey Syndrome (Richard et al., 2004) and remains otherwise unexamined. N14K 
and D50N mutants are linked to KIDS which is one of the most severe Cx26-linked skin 
disorders. Patients present with erythrokeratoderma, PPK, and frequent cutaneous infections 
can lead to fatal septicemia early in life (Coggshall et al., 2013). We found these mutants 
strongly induced cell death such that meaningful channel function information was 
unattainable. However, reports suggest they form “leaky” hemichannels when expressed in 
Xenopus oocytes where they induce blebbing and substantially reduce cell viability (Lee et al., 
2009; Sanchez et al., 2016; Sanchez et al., 2013). Cx26 hemichannels are sensitive to 
hyperpolarization by extracellular Ca2+ such that they remain closed under physiological 
conditions (Fasciani et al., 2013). However, reduced Ca2+ sensitivity by N14K, D50N, and 
several other KIDS mutants promotes hemichannel opening that can diminish transmembrane 
ion gradients and release molecules including ATP that affect cell viability (Sanchez and 
Verselis, 2014). Excessive ATP release is also known to stimulate purinergic signaling 
capable of mobilizing intracellular Ca2+, and releasing pro-inflammatory cytokines (Burnstock 
et al., 2012). In the epidermis, these mutants may also be able to disrupt the normal epidermal 
Ca2+ gradient and lipid processing (Bosen et al., 2015), which can result in barrier defects and 
a compensatory hyperproliferative response that drives hyperkeratosis in KIDS (Garcia et al., 
2016a). Interestingly, N14 and D50 are pore-lining residues (Garcia et al., 2016a) suggesting 
that changes to the structure of the Cx26 channel pore can produce the aberrant hemichannel 
properties that stand at the forefront of KIDS skin pathogenesis.  
The N54K is linked to moderately severe Bart-Pumphrey Syndrome featuring PPK, knuckle-
pads, leukonychia, and deafness, meanwhile the S183F mutant is linked to PPK with deafness. 
Although no well-defined pathogenic mechanisms for PPK have been established, our 
findings suggest that the high intracellular retention of N54K and S183F mutants is a common 
characteristic of Cx26 mutants linked to PPK. Indeed, this trafficking defect has been indicated 
in previous reports (de Zwart-Storm et al., 2008a; Martin and van Steensel, 2015; Marziano et 
al., 2003; Thomas et al., 2005). The patient with Bart-Pumphrey Syndrome harbouring the 
N54K Cx26 mutant in (Richard et al., 2004) was reported to have a compensatory increase in 
epidermal Cx30 expression. N54 is an invariably conserved residue in the connexin family 
among numerous species (Richard et al., 2004) and forms hydrogen bonds with L56 from the 
opposing hemichannel (Maeda et al., 2009). Interestingly, we found that the N54K mutant 
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impaired Cx30 trafficking and dye transfer, suggesting that Cx30 compensation may act to 
overcome a trans-dominant hindrance of Cx26:Cx30 heteromeric gap junction formation 
between keratinocytes. This study, and only a handful of others (Common et al., 2003; Di et 
al., 2005; Donnelly et al., 2012; Man et al., 2007; Mhaske et al., 2013) investigated Cx26 
mutants in a relevant keratinocyte model rather than connexin-deficient reference cells. We 
found that only REKs expressing the N54K mutant had reduced dye transfer. This suggests 
that N54K Cx26 may also exert trans-dominant effects on endogenous Cx43 which may be an 
important etiological factor in Bart-Pumphrey Syndrome skin. Recently, Shuja and colleagues 
demonstrated that S183F Cx26 does not form gap junctions or hemichannels in Xenopus 
oocytes and junctional conductance was reduced in cells co-expressing Cx43 (Shuja et al., 
2016). We also found that the S183F mutant inhibited dye transfer in cells co-expressing Cx30, 
pointing towards trans-dominant interactions of co-expressed connexins as a mechanism of 
disease. Since S183 is a highly conserved residue in the connexin family among many species 
(de Zwart-Storm et al., 2008b), we suggest that the S183 residue may have an indirect role in 
inter-protomer binding. Additionally, moderately leaky heteromeric hemichannels formed by 
S183F Cx26 and Cx43 (Shuja et al., 2016), similar to those composed of S17F Cx26 and Cx43, 
may also contribute to PPK. Nevertheless, our findings provide additional evidence for the 
impact of trans-dominant interactions between connexins in skin disease where disease 
severity may be linked to the extent of trans-dominant influence – particularly in skin regions 
exposed to greater mechanical stress.  
In this study, only the M163V mutant is linked to hearing loss without added skin disease. 
Since Cx26 is proposed to play an important role in potassium recycling in the inner ear 
(Jagger and Forge, 2015) and dozens of hearing loss Cx26 mutants display reduced or no gap 
junction function (Xu and Nicholson, 2013), it is not surprising that we found the M163V 
mutant had a dominant negative effect on Cx26. However, Cx30 is also highly expressed with 
Cx26 in the inner ear (Jagger and Forge, 2015) such that compensation might be able to rescue 
hearing. However, several studies have shown that Cx30 cannot functionally compensate for 
Cx26 in the inner ear (Cohen-Salmon et al., 2002; Qu et al., 2012; Teubner et al., 2003). This 
may explain why the M163V mutant leads to hearing loss despite that HeLa cells co-
expressing the M163V mutant and Cx30 passed dye at levels not unlike HeLa cells expressing 
Cx30 or Cx30 co-expressed with Cx26. Including our findings from syndromic mutants, we 
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suggest that mutants with trafficking defects, trans-dominant properties, and that induce cell 
death lead to skin phenotypes, whereas mutants with reduced gap junction function, but do not 
interfere with other co-expressed connexins produce non-syndromic hearing loss.  
Human epidermis expresses 7 different connexins in overlapping populations of keratinocytes 
(Di et al., 2001; Martin et al., 2014) making the epidermis a more robust system compared to 
the cochlea. Fortunately, this high degree of redundant intercellular communication affords 
the epidermis with resiliency in response to GJB2 mutations that have minor effects on protein 
function. Because fewer connexin types are expressed within the cochlea and compensation 
may be limited, small perturbations in connexin function are capable of disrupting normal 
hearing. This may speak to the reason why GJB2 mutations almost never produce skin disease 
alone yet Cx26-linked syndromic and non-syndromic deafness is ordinary. While the majority 
of autosomal dominant GJB2 mutations produce hearing loss in addition to skin disease, we 
posit that strongest predictors of syndromic disease severity actually stem from the trans-
dominant status and gain-of-function properties of Cx26 mutant gap junctions and 
hemichannels. Finally, this study provides evidence in support of genetic screening when 
faced with complex syndromic diseases.  
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Chapter 3 
  Mice harboring disease-linked Cx26 and Cx30 mutants 
display volar skin abnormalities but retain most wound 
healing properties.  
 
Here we generated a novel, viable, and fertile mouse (Cx26K14-S17F/+) which expresses the 
keratitis-ichthyosis-deafness syndrome (KIDS) mutant (S17F Cx26) driven from the keratin 
14 promoter. This mutant mouse mirrors several Cx26-linked human skin pathologies 
suggesting that the etiology of Cx26-linked skin disease indeed stems from epidermal 
expression of the Cx26 mutant. Cx26K14-S17F/+ foot pad epidermis formed severe palmoplantar 
keratoderma which expressed elevated levels of Cx26 and filaggrin. Primary keratinocytes 
isolated from Cx26K14-S17F/+ neonates had reduced GJIC and migration. Furthermore, Cx26K14-
S17F/+ mouse skin healed normally after wounding but exhibited abnormal epidermal 
remodeling. Mice harbouring the Clouston Syndrome A88V Cx30 mutant (Cx30A88V/+, 
Cx30A88V/A88V) showed no skin abnormalities or wound healing defects suggesting that 
compared to humans, Cx30 may have a less critical role in mouse epidermis. Taken together, 
we suggest that Cx26 helps regulate keratinocyte differentiation, especially in palmoplantar 
skin, but mice harbouring Cx26 and Cx30 mutants retain most skin wound healing properties.   
 
A version of this chapter will be submitted for publication before the end of the year. 
Authors: Eric R. Press, Katanya C. Alaga, Kevin Barr, Qing Shao, Felicitas Bosen, Klaus 
Willecke and Dale W. Laird 
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3.1 Introduction 
Gap junction channels allow for direct intercellular communication by facilitating the passage 
of small molecular messengers between the cytosol of adjacent cells (Alexander and Goldberg, 
2003). Individual cells may also exchange signaling molecules with the extracellular 
environment through hemichannels at the cell membrane (Saez et al., 2005). Gap junction 
channels are composed of docked hemichannels from adjacent cells, each of which contains 
six oligomerized connexin (Cx) subunits. Connexins comprise a family of transmembrane 
proteins that have large clinical significance due to the discovery of abundant disease-causing 
mutations in connexin genes. Notably, mutations in the genes encoding Cx26 and Cx30 cause 
syndromic diseases where patients suffer from hearing loss and a broad range of skin 
abnormalities that vary in localization and severity (Avshalumova et al., 2014; Martin and van 
Steensel, 2015; Scott et al., 2012). Interestingly, Cx26 and Cx30 mutants can give rise to 
diseases affecting one or multiple tissues and mutants with similar functional characteristics 
often lead to similar phenotypes, suggesting specific functional anomalies are closely tied to 
disease outcomes (Martin and van Steensel, 2015; Xu and Nicholson, 2013). Not surprisingly 
however, Cx26 and Cx30 are both expressed in the cochlea and epidermis, and they share a 
similar localization pattern within the epidermal strata (Yum et al., 2007), and likely form 
heteromeric channels between keratinocytes. 
The human epidermis expresses up to 7 distinct connexin proteins in overlapping populations 
of keratinocytes highlighting the complexity of gap junctional intercellular communication 
(GJIC) in this tissue (Di et al., 2001). Two distinct mouse models demonstrated that persistent 
epidermal Cx26 expression promoted a hyperproliferative, inflammatory response suggesting 
a delicate balance of individual connexins may be required for epidermal health (Djalilian et 
al., 2006). A key factor likely involved in regulating keratinocyte differentiation is an 
increasing intracellular Ca2+ gradient between keratinocytes of the stratum basale and stratum 
granulosum (Adams et al., 2012; Bikle et al., 2012). Gap junction channels are known to pass 
signaling molecules such as IP3 that regulate intracellular Ca2+ handling, which may have a 
profound influence on the synthesis and assembly of skin barrier components such as filaggrin 
and ceramides (Bosen et al., 2015; Sandilands et al., 2009). Furthermore, it is well known that 
following cutaneous wounding, multiple connexins including Cx26, Cx30, and Cx43, are 
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dynamically regulated within the epidermis suggesting they play a major role in coordinating 
wound healing events such as keratinocyte proliferation, migration, and differentiation 
(Brandner et al., 2004; Churko and Laird, 2013). In fact, numerous studies employing Cx43 
knock-down strategies have demonstrated beneficial wound healing outcomes (Churko et al., 
2012; Coutinho et al., 2003; Ghatnekar et al., 2015; Mori et al., 2006; Qiu et al., 2003) which 
strongly promotes Cx43 as a therapeutic target for chronic wounds. Despite the evidence 
supporting the influence of connexins on epidermal health, the roles of Cx26 and Cx30 in the 
skin are still incompletely understood, particularly in the context of healing wounds. 
Several Cx26 mutants, including the S17F mutant, are linked to keratitis-ichthyosis-deafness 
syndrome (KIDS); a rare and severe autosomal dominant disease featuring generalized 
dry/scaly skin, patchy erythematous keratoderma and palmoplantar keratoderma (Coggshall 
et al., 2013). In some cases, frequent cutaneous infections lead to fatal septicemia early in life 
(Coggshall et al., 2013). In vitro ectopic expression studies have revealed hyperactive or 
“leaky” hemichannels as a likely pathogenic characteristic of KIDS mutants (Garcia et al., 
2015; Lee et al., 2009). Interestingly, the S17F mutant does not form functional gap junction 
channels or hemichannels on its own (Garcia et al., 2015; Richard et al., 2002), but rather 
forms heteromeric hyperactive hemichannels when co-expressed with wild type Cx26 or Cx43 
(Garcia et al., 2015). A transgenic mouse that globally expresses the S17F mutant replicates 
several KIDS phenotypes in addition to features typically associated with separate Cx26-
linked diseases (Schutz et al., 2011). However, because these mice have low viability and it is 
still unknown how the mutant specifically affects the epidermis, we generated a tissue-specific 
mouse that harbours the S17F mutant in the epidermis (Cx26K14-S17F/+). The A88V Cx30 
mutant is known to cause the highly variable Clouston Syndrome (Common et al., 2003); a 
rare autosomal dominant disease that presents with PPK, regional hyperpigmentation, 
alopecia, nail dystrophy, clubbed fingers, and in some cases hearing loss (Kibar et al., 2000; 
Sugiura et al., 2013). The A88V mutant forms a small number of partially functional gap 
junctions (Berger et al., 2014) in addition to hyperactive hemichannels that release excessive 
ATP into the extracellular space and induce cell death (Essenfelder et al., 2004). A transgenic 
mouse that globally expresses the A88V Cx30 mutant (Cx30A88V/A88V) exhibits 
hyperproliferative sebaceous glands leading to a greasy coat as well as mild hyperkeratosis of 
foot pad skin (Bosen et al., 2014). While numerous abnormal cellular characteristics of Cx26 
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and Cx30 mutants have been identified, and several transgenic mice have been generated to 
model human connexin-linked skin disorders, the etiology of these diseases as well and their 
impact on cutaneous wound healing remains poorly understood.  
Therefore, by using our novel Cx26K14-S17F/+ mouse and the Cx30A88V/A88V mouse described in 
Bosen et al. (2014), we aimed to assess how Cx26 and Cx30 mutants produce skin disease to 
ultimately gain further insight into the role of these proteins in healthy skin. We found that 
S17F Cx26, but not A88V Cx30 produced severe PPK, wherein expression of Cx26 as well 
as filaggrin was elevated in foot pad skin indicating deregulated differentiation. Moreover, 
primary keratinocytes from Cx26K14-S17F/+ mice had reduced gap junctional coupling and 
changes in migration. Lastly, both Cx26 and Cx30 mutant mice retain most of the properties 
associated with active wound healing.  
 
3.2 Materials and Methods 
3.2.1 Genetically-Modified Mice 
All animal experiments were approved by the Animal Use Committee at Western University 
in accordance with guidelines from the Canadian Council for Animal Care. Cx26K14-S17F/+ mice 
(hereafter referred to as S17F/+) were generated in-house, on a mixed C57BL/6 and 129Sv 
background. Heterozygous floxed mice (Cx26floxS17F/+ - generated in Schütz et al, (2011) and 
obtained from Dr. K. Willecke) were crossed with homozygous keratin 14 Cre mice 
(Gjb2tm2.2Kwi/Cnrm, Jackson Labs) which were obtained from Dr. L. Dagnino. S17F/+ mice 
express S17F Cx26 heterozygously in basal cells of the epidermis, as well as the oral and 
vaginal epithelium (Dassule et al., 2000). Cx30A88V/+ and Cx30A88V/A88V mice, (hereafter 
referred to as A88V/+ and A88V/A88V, respectively) were generated by Bosen and 
colleagues (Bosen et al., 2014) and obtained from Dr. K. Willecke. Due to the differences in 
genetic background between mouse strains, all animal experiments used wild-type littermates 
as controls (hereafter referred to as Control). Roughly equal proportions of male and female 
mice were used for all experiments. 
 
!!
61!
3.2.2 Mouse Genotyping 
Ear notches at the time of weaning were incubated overnight at 58°C in a proteinase K solution 
composed of 0.6 mg of proteinase K (Cat# 25530-049; Invitrogen) dissolved in buffer 
containing 20 mM Tris Cl pH 8.3, 50 mM KCl, 2.5 mM MgCl2, and 0.5% Tween 20. The 
digested tissue solution was incubated for 10 minutes at 95°C and DNA amplification was 
carried out by polymerase chain reaction (PCR). PCR mixtures included 10x PCR buffer (Cat# 
1360566; Invitrogen), 50 mM MgCl (Cat# 11392196; Invitrogen), 10 µm dNTPs (Cat# 10297-
018; Invitrogen), and Platinum Taq polymerase (Cat# 10966-018; Invitrogen). Samples were 
run for 40 cycles with the annealing temperature set to 57°C for S17F/+ samples, and 65°C 
for the A88V/+ and A88V/A88V samples. PCR products were run on a 2% agarose gel 
including 200 µg of ethidium bromide, and gels were visualized under ultra-violet light. 
3.2.3 Skeletal Staining 
Seven day old mice were euthanized, neatly eviscerated to reveal the skeleton, and the skeleton 
was stained according to a modified protocol from (McLeod, 1980). Skeletons were 
dehydrated in 95% overnight and fixed in acetone for 24 hours. Skeletons were stained for 4 
days using a solution containing 0.015% alcian blue, 0.05% alizarin red, and 5% acetic acid 
in 70% ethanol as described in (Wang et al., 2007b). Finally, skeletons were cleared using 1% 
KOH in ddH20 until the stained vertebrae and intervertebral disks were clearly visible. Two 
animals per genotype were used for skeletal staining.  
3.2.4 Micro-Computed Tomography 
Micro-computed tomography (µCT) scans of euthanized 3-month-old S17F/+ and control 
whole mouse bodies were obtained using the eXplore speCZT µCT scanner (GE Healthcare) 
at Robarts Research Institute (London, ON, Canada) to assess the bone structure underlying 
the S17F/+ truncated tail or skeletal abnormalities in the digits. Further technical specifications 
and image processing techniques are outlined in (Caskenette et al., 2016). Briefly, scans were 
acquired with a voxel size of 100 µm3 and 3D composite images were reconstructed and 
manipulated using MicroView software (GE Healthcare Biosciences). One S17F/+ and one 
control mouse were used to create isosurface images. 
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3.2.5 Tissue Lysates and Immunoblotting 
Foot pad skin was dissected, frozen with liquid nitrogen, and pulverized with a cold mortar 
and pestle over dry ice. Lysates were generated by dissolving the pulverized tissue in 2x 
immunoprecipitation buffer (containing 1% Triton X-100, 150 mM NaCl, 10 mM Tris, 1 mM 
EDTA, 1 mM EGTA, 0.5% NP-40, 1.0 mg of NaF, 1.0 mg of Na3VO4, and a Complete Mini 
protease inhibitor tablet (Roche Cat# 10570500)). Lysates were stored at -80°C until 
electrophoresis. Protein concentration was determined with standard bicinchoninic acid assay. 
Lysates were run on a 12% polyacrylamide gel using SDS-PAGE and protein was transferred 
to nitrocellulose membranes with the iBlot dry transfer system (7 minute transfer). Membranes 
were blocked in 2% BSA in PBST and probed with 1:1000 mouse anti-Cx26 (Invitrogen Cat# 
138100), 1:1000 rabbit anti-Cx30 (Invitrogen Cat# 71-2200), 1:5000 rabbit anti-Cx43 (Sigma 
Cat# 112M4824), 1:5000 mouse anti-GAPDH (Millipore Cat# 2145925), 1:1000 mouse anti-
keratin 14 (ThermoFisher Cat# MA5-11599), 1:1000 rabbit anti-filaggrin (Covance Cat# 
PRB-417P), and 1:400 rabbit anti-proliferating cell nuclear antigen (PCNA) (Santa Cruz Cat# 
FL-261:sc-7907) antibodies. Secondary antibodies included AlexaFluor680 (Cat# A21076; 
Life Technologies) and IRDye800 (Cat# 24058; Rockland) and membranes were visualized 
using the Odyssey infrared imaging system. An unpaired t-test (for S17F/+) or one-way 
ANOVA (for A88V/+ and A88V/A88V) was performed on the mean intensity (K counts) of 
biological replicates. 
3.2.6 Immunohistochemistry and Immunofluorescence Imaging 
Foot pad skin was fixed with 10% neutral buffered formalin overnight at 4˚C, paraffin 
embedded, sectioned, and stained with hematoxylin and eosin for histological analysis 
according to (Stewart et al., 2013). Separate tissue samples were also fixed, cryopreserved in 
30% sucrose in PBS, embedded in 1% low melting point agarose containing 18% sucrose and 
0.01% NaN3, flash frozen with liquid nitrogen, and cryosectioned for immunofluorescent 
imaging. Frozen sections were blocked in 3% BSA + 0.2% Triton X-100 and labeled with 
1:400 rabbit anti-Cx26 (Invitrogen Cat# 512800), 1:400 rabbit anti-Cx30, 1:500 rabbit anti-
Cx43, 1:200 mouse anti-keratin 14, 1:200 rabbit anti-filaggrin, and 1:400 rabbit anti-Ki67 
(Abcam Cat# ab66155). The secondary antibodies used were 1:500 anti-rabbit Alexa488 (Life 
Technologies Cat# A11008), 1:500 anti-rabbit Alexa555 (Life Technologies Cat# A21429), 
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and 1:500 anti-mouse Alexa488 (Life Technologies Cat# A11017). Sections were counter-
stained with Hoechst, mounted using Airvol, and imaged with a Zeiss LSM 800 confocal 
microscope equipped with ZenWorks software. Images were captured with a 40x water 
immersion objective.  
3.2.7 Wound Healing Assays 
Three month old mice were anesthetized with isoflurane, administered analgesics 
subcutaneously, then a small section of dorsal hair was shaved and depilated with Nair, and 
the skin was sterilized using the standard 3-stage preparation. Wounds were performed using 
a 5mm human punch biopsy to remove the full thickness of the skin as described in (Churko 
et al., 2011b). Briefly, dorsal skin was held taut and a punch biopsy tool was twisted on the 
skin with light pressure until a full-thickness circle of skin was removed. Skin tension was 
released and allowed to retract for approximately 30 seconds before imaging. Wound 
inspection and imaging was performed the day of surgery, and every second day until fully 
healed. Wound sizes were measured using ImageJ in a blinded fashion. A two-way ANOVA 
was performed on the mean wound area of at least 6 mice per genotype.  
3.2.8 Cell Lines 
Connexin-rich rat epidermal keratinocytes (REKs) were originally described in (Baden and 
Kubilus, 1983) were provided by Dr. V. Hascall. Cells were grown in DMEM (Life 
Technologies Cat# 11965-092) supplemented with fetal bovine serum (Gibco Cat# 12484-
028), 2 mM L-glutamine (Life Technologies Cat# 25030-081), penicillin and streptomycin 
according to (Penuela et al., 2007). 
3.2.9 Primary Murine Keratinocyte Culture 
Keratinocytes were isolated from neonatal mice (P2-P3) according to (Churko et al., 2012) 
with minor procedural adjustments. Briefly, complete body skin was carefully dissected from 
neonates was rinsed in Ca2+ and Mg2+ free PBS (Invitrogen Cat# 14190-144) containing 5 
µg/mL gentamycin (Invitrogen Cat# 15750-060). Skins were floated dermis side down over 
1.5 mL of 50 cU/mL dispase (Corning Cat#354235) at 4˚C overnight with gentle rocking. The 
epidermis was gently separated from the dermis, minced with sterile scissors, and incubated 
in 0.25% trypsin-EDTA (Invitrogen Cat# 25200-056) for ~10 minutes at 37°C. The cell 
!!
64!
suspension was removed and placed into 1.5 mL of Keratinocyte Serum-Free Medium (K-
SFM) (Invitrogen Cat# 37010-022) supplemented with 1.4 mM CaCl2 and 1.5 mL of stock 
trypsin neutralizer solution (Invitrogen Cat# R-002-100), and centrifuged. The pellet was 
resuspended in K-SFM supplemented with 0.05 mM CaCl2, poured through a 70 µm cell 
strainer (Falcon Cat# 21008-952), and plated in dishes pre-coated with 50 µg/mL collagen I 
(BD Biosciences Cat# 354236). The next day, cells were washed 2 times with Ca2+ and Mg2+ 
free PBS then incubated in K-SFM containing 1.4 mM CaCl2. Cells were used for experiments 
between 48-72 hours following initial plating. 
3.2.10 Calcein-AM Dye Recovery 
Primary mouse keratinocytes and REKs were grown on 35mm glass bottom dishes and pre-
loaded for 10 minutes at 37˚C in a 0.3 mM isotonic glucose solution containing 2 µl/mL 
calcein-AM dissolved in DMSO. Cells were washed in PBS and photobleached to 20% of 
original fluorescence intensity with a 488 nm argon laser at 50% strength. Images were 
subsequently captured every 10 seconds for approximately 10 minutes with a LSM 800 Zeiss 
confocal microscope and a 40x water-immersion lens. Image series were exported to ImageJ 
and fluorescence recovery of photobleached cells were measured using the Time Series 
Analyzer V3 plugin. Fluorescence recovery curves displayed summarized data and a one-way 
ANOVA was performed on the area under the curve (AUC) of biological replicates.  
3.2.11 Scratch-Wound Assay 
Primary mouse keratinocytes were seeded at 1x106 cells per 35 mm gridded dish (Sarstedt 
Cat# 83.1800.001). Culture dishes were pre-coated with collagen as previously described and 
following 48 hours of incubation in K-SFM containing 1.4 mM CaCl2, cells were rinsed with 
Ca2+ and Mg2+ free PBS and scraped with a P1000 pipette tip. Cells were then replenished 
with K-SFM containing no supplements or CaCl2 and images of 10 identical sections per dish 
(0.5 mm2), were captured at 24 and 48 hours following the scrape. For each image, the gap 
between keratinocyte fronts was measured in 5 similar regions and an unpaired t-test (S17F/+ 
cultures) or a one-way ANOVA (A88V/+ and A88V/A88V cultures) was performed on the 
calculated migration distances of replicates. 
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3.2.12 Scrape-Load Assay 
Primary mouse keratinocytes were seeded at 1x106 cells per 35 mm dish and incubated in K-
SFM containing 1.4 mM CaCl2 for 48 hours. Cells were washed twice with warm HBSS and 
then incubated in HBSS containing 2.5% Lucifer Yellow and 1% DiI. Cells were scraped with 
a sharp surgical blade and incubated at 37˚C for 5 minutes. Cells were then washed 3 times 
with warm HBSS and images with a Leica inverted epifluorescent microscope using a 20x 
objective. Five similar fields were imaged for each experimental replicate. For each image, 
Lucifer Yellow transfer distance minus DiI transfer distance was calculated, and a one-way 
ANOVA was performed on the calculated means of biological replicates. 
3.2.13 Statistical Analysis 
Graph Pad Prism version 6 was used for all statistical analysis and statistical significance was 
noted when p<0.05. All student’s t-tests were two tailed. All histogram values represent the 
mean + SEM. 
 
3.3 Results 
3.3.1 Epidermal expression of S17F Cx26, but not A88V Cx30, results in severe 
skin features plus comorbidities  
S17F/+ mice harbouring the mutated Gjb2 gene only in cells expressing keratin 14 (basal 
keratinocytes) resulted in a tissue-defined transgenic mouse that expressed the S17F mutant 
under the control of the endogenous Cx26 promoter. This primarily epidermis expression 
profile was capable of reproducing KIDS skin features in a novel mutant mouse in addition to 
several intriguing phenotypes (Fig. 3.1). S17F/+ pups were visibly smaller and had red, dry, 
scaly skin (Fig. 3.1A). PCR analysis of skin tissue confirmed the heterozygous expression of 
S17F Cx26 (Fig. 3.1B). Contrary to global Cx26S17F/+ mice (Schutz et al., 2011), our tissue-
defined S17F/+ mice had no loss of viability and were born in equal proportion to wild type 
littermates (Fig. 3.1C). Interestingly, S17F/+ mice were approximately 15% smaller by 3 
months of age (Fig. 3.1E), and had a shortened tail (Fig. 3.1D) which coincided with the 
formation of a cutaneous bulb at the distal tail by post-natal day 7 (Fig. 3.1F, G). This appeared 
to impair proper vertebral formation within the bulb preventing normal tail growth (Fig. 3.1H).  
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Figure 3.1 
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Fig. 3.1. S17F/+ mice mimic KIDS skin characteristics and have several additional 
phenotypes. (A) S17F/+ neonates were smaller and visually distinguishable from control 
littermates. (B) Skin sample PCR amplification confirms the heterozygous expression of S17F 
Cx26 in S17F/+ mice. (C) Litters contained equal portions of S17F/+ and control pups with 
no loss of mouse viability (n ≥ 148). (D) Representative photos of 3-month-old S17F/+ and 
control mice reveal moderate differences in size but a pronounced tail phenotype. (E) Whole 
mouse weights at 3 months of age showed S17F/+ mice are ~15% smaller (**p<0.01, N ≥ 17). 
(F) Skeletal stains of P7 tails revealed vertebral malformations underlying the tail phenotype 
in S17F/+ mice. (G) Cross-section of a distal tail paraffin section stained with hematoxylin 
and eosin revealed grossly thickened epidermis. (H) µCT scans of 3-month-old mouse tails 
revealed vertebral abnormalities in S17F/+ mice. Red arrows in (H) denote the relative 
locations of cross sections in (G). 
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Severe PPK was clearly visible in adult S17F/+ mice in which foot pad epidermis displayed 
protruding hyperpigmented calluses (Fig. 3.2A). Histological examination confirmed a gross 
thickening of vital epidermal layers (stratum basale, spinosum, and granulosum) (Fig. 3.2B). 
In addition to the bulbous region at the distal tail, middle regions of tail epidermis also 
displayed moderate thickening of these vital layers (Fig. 3.2B). 
The Cx30 mutant mice (homozygotes indicated as A88V/A88V and heterozygotes as A88V/+) 
were previously described in (Bosen et al., 2014) and reported to have hyperproliferative 
sebaceous glands and mild hyperkeratosis of foot pad skin. Besides a greasy matted coat, we 
found no cutaneous phenotypes, nor a measureable thickening of foot pad epidermis (Fig. 
3.3A).   
3.3.2 S17F Cx26, but not A88V Cx30, disrupts keratinocyte differentiation in 
foot pad epidermis 
Tissue lysates of hind foot pad skin from 3-month-old S17F/+ mice showed elevated levels of 
Cx26 (Fig. 3.2C). While no differences in Cx30 or Cx43 levels were detected in mutant 
epidermis, all three connexins had large overlapping distribution profiles that were clearly 
distinguishable from control epidermis (Fig. 3.2D). Each connexin formed abundant gap 
junction plaques indicating that the S17F Cx26 mutant does not impair connexin trafficking 
in vivo. S17F/+ epidermis also had normal levels of keratin 14 (expressed in basal 
keratinocytes) but a greater amount of filaggrin (expressed in the stratum granulosum and 
corneum) which was found in numerous suprabasal keratinocyte layers (Fig. 3.4A, B). 
Epidermal proliferation was not affected based on Ki67 (Fig. 3.4C) and proliferating cell 
nuclear antigen (PCNA) assessment (Fig. 3.4D). Foot pad epidermis from A88V/+ and 
A88V/A88V mice had no changes in epidermal connexin expression level (Fig. 3.3B) or 
distribution pattern (Fig. 3.3C). Additionally, A88V/+ and A88V/A88V epidermis were 
similar to control epidermis for keratin and filaggrin expression, as well as proliferation (Fig. 
3.5). Together these findings suggest epidermal S17F Cx26 but not A88V Cx30 disrupts 
keratinocyte proliferation-differentiation balance and promotes the formation of PPK in mice.   
3.3.3 Primary keratinocytes harvested from S17F/+ mice exhibit reduced GJIC 
and collective cell migration 
Keratinocytes were harvested from newborn connexin mutant mice and WT littermates to 
assess the influence of physiological levels of S17F Cx26 and A88V Cx30 on keratinocyte 
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Figure 3.2 
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Fig. 3.2. S17F/+ mice display thicker foot pad and tail epidermis, and deregulated 
epidermal connexin expression. (A) 3-month-old S17F/+ mice exhibit severe foot pad 
epidermal thickening including abnormal non-squamous keratinocytes in suprabasal layers as 
well as thicker tail epidermis compared to controls (B) (unpaired t-test, ***p<0.001, 
****p<0.0001, N ≥ 7). (C) Foot pad skin lysates from 3-month-old S17F/+ mice exhibited 
elevated levels of Cx26 expression compared to controls (unpaired t-test, **p<0.01, ns = 
p>0.05, N ≥ 10). (D) Cryosections of 3-month-old S17F/+ foot pad epidermis revealed that 
Cx26, Cx30, and Cx43 formed abundant gap junctions in a broad range of keratinocyte layers. 
Complete and dashed lines denote the dermis-epidermis boundary and stratum granulosum-
corneum boundary, respectively. Scale bar in (A-upper) = 50µm (inset = 10µm), (A-lower) = 
10µm, (D) = 20µm (inset = 20µm).  
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Figure 3.3 
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Fig. 3.3. A88V/+ and A88V/A88V mice display normal foot pad epidermis and connexin 
expression. (A) Foot pad skin from 3-month-old mutant mice displayed normal epidermal 
appearance and thickness (ns = p>0.05, N ≥ 5) and no differences in Cx26, Cx30, and Cx43 
expression (B) (ns = p>0.05, N = 7). (C) Foot pad skin cryosections from 3-month-old mutant 
mice also displayed Cx26, Cx30, and Cx43 formed abundant gap junction plaques (arrows in 
insets) and were expression in discrete keratinocyte layers. Complete and dashed lines denote 
the dermis-epidermis boundary, and the stratum granulosum-corneum boundaries, 
respectively. Scale bar in (A) = 50µm (C) = 20µm, (inset = 20µm). 
 
 
 
 
!!
73!
Figure 3.4 
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Fig. 3.4. S17F/+ mice display abnormal keratinocyte differentiation in foot pad 
epidermis. (A) Foot pad skin lysates from 3-month-old S17F/+ mice have elevated filaggrin, 
but normal keratin 14 levels compared to controls (**p<0.01, N ≥ 10). (B) 3-month-old foot 
pad epidermis labeled for filaggrin (red) and keratin 14 (green) revealed elevated filaggrin 
labelling of suprabasal keratinocytes in S17F/+ epidermis. (C) 3-month-old foot pad epidermis 
labeled for Ki67 (red) and lysates immunoblotted for PCNA (D) demonstrated unaltered levels 
of cell proliferation in S17F/+ epidermis (ns = p>0.05, N ≥ 10). Complete and dashed lines 
denote the dermis-epidermis boundary and stratum granulosum-corneum boundary, 
respectively. Scale bar in (B) and (C) = 20µm.  
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Figure 3.5 
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Fig. 3.5. A88V/+ and A88V/A88V mice display normal keratinocyte differentiation and 
proliferation in foot pad epidermis. (A) 3-month-old A88V/+ and A88V/A88V foot pad 
skin cryosections revealed similar localization of immunolabelled filaggrin (red) and keratin 
14 (green) which were also expressed at normal levels in foot pad skin lysates (B) (ns = 
p>0.05, N = 7). Foot pad epidermis immunolabelled labelled for Ki67 (C) and lysates 
immunoblotted for PCNA (D) displayed unaltered levels of cell proliferation in A88V/+ and 
A88V/A88V epidermis (ns = p>0.05, N=7). Scale bar in (A, C) = 20µm. 
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and migration. Similar to a well characterized rat epidermal keratinocyte (REK) cell line (Fig. 
3.6A), nearly all primary cells labeled thoroughly with keratin 14 and intermediate filaments 
were clearly visible under high magnification (Fig. 3.6B), indicating a highly pure 
keratinocyte population. In dense clustered regions, cells stratified and increased filaggrin 
expression, mimicking the behavior of stratified keratinocytes in live epidermis (Fig. 3.6B). 
Keratinocyte cultures were incubated in media containing 1.4mM CaCl2 for 24 hours to 
stimulate differentiation and the subsequent expression of Cx26 and Cx30. Compared to 
controls, S17F/+ cultures appeared to form fewer and smaller Cx26 gap junction plaques 
between cells, and demonstrated reduced fluorescence recovery following photobleaching 
(Fig. 3.7A, B). Furthermore, S17F/+ cultures displayed reduced collective migration in 
response to scratch wounds (Fig. 3.7C). Keratinocytes from A88V/A88V mice also appeared 
to form far fewer Cx26 and Cx30 gap junction plaques compared to A88V/+ and control 
cultures (Fig. 3.8A). Interestingly, A88V/A88V keratinocytes displayed no differences in 
GJIC yet demonstrated increased collective migration in response to scratch wounds (Fig. 
3.8C). Together these findings suggest Cx26 intercellular communication may influence 
keratinocyte migration whereas Cx30 may influence migration in a GJIC independent 
mechanism.  
3.3.4 S17F/+ mice display irregular dorsal skin remodeling and tail skin wound 
healing  
Since dynamic regulation of Cx26 and Cx30 coincides with different stages of wound healing, 
we tested whether mutant Cx26 or Cx30 mutant mice had any overt wound healing defects. 
Between 3 and 4 months of age, a punch biopsy of depilated dorsal skin created a wound in 
which healing was monitored. S17F/+ mice displayed no differences in wound size at any 
stage of recovery (Fig. 3.9A) however, repaired epidermis was measurably thicker in S17F/+ 
mice suggesting possible aberrant epidermal remodeling in response to the wound (Fig. 3.9B). 
No differences in wound healing or abnormalities in repaired epidermis were found in Cx30 
mutant mouse dorsal wounds (Fig. 3.9 C, D).  
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Figure 3.6 
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Fig. 3.6. Isolated keratinocyte cultures are highly pure. Similar to well-characterized REKs 
(A), highly pure primary keratinocyte cultures (B) immunolabelled extensively with keratin 
14 (green) and demonstrated elevated filaggrin expression in regions where cells began to 
stratify (left). Individual keratin filaments were visible under high magnification (right). Scale 
bar in (A) = 10µm, (B-left) = 20µm, (B-right) = 10µm. 
wherein patients express connexin mutants with defects in cellular communication (van 
Steensel, 2004). The epidermis relies on complex GJIC to coordinate a balance of cell 
proliferation and differentiation for the maintenance of rapid physiological turnover and  
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Figure 3.7 
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Fig. 3.7. Keratinocytes isolated from S17F/+ neonates have reduced GJIC and collective 
cell migration. (A) S17F/+ keratinocyte cultures appeared to form fewer and smaller Cx26 
gap junctions between cells. (B) S17F/+ keratinocytes have reduced calcein-AM fluorescence 
recovery after photobleaching compared to controls indicative of reduced GJIC (*p<0.05, N 
= 8). (C) Collective keratinocyte migration in response to scratch-wounds was reduced in 
S17F/+ cultures compared to controls (***p<0.001, ****p<0.0001, N = 4 separate 
experiments). Scale bar in (A) = 20µm (inset = 10µm), (B) = 10µm, (C) = 100µm. 
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Figure 3.8 
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Fig. 3.8. Keratinocytes from A88V/A88V mice display normal GJIC but increased 
collective cell migration. (A) Keratinocytes from A88V/A88V mice appeared to form fewer 
gap junction plaques compared to control and A88V/+ keratinocytes. (B) Following scrape-
loading, mutant keratinocytes displayed similar Lucifer yellow dye transfer to controls (ns = 
p>0.05, N = 4). DiI is a gap junction impermeable tracer to denote keratinocytes at the scrape 
edge denoted by the dashed line. (C) A88V/A88V keratinocytes exhibited increased collective 
cell migration compared to A88V/+ and control keratinocytes (**p<0.01, ***p<0.001, 
****p,0.0001, N = 4). Scale bar in (A) = 10µm, (B) = 20µm, (C) = 50µm. 
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Figure 3.9 
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Fig. 3.9. Mutant mice display normal wound closure, but S17F/+ mice exhibit abnormal 
epidermis remodeling. (A) Dorsal skin wound closure was found to be normal in S17F/+ as 
well as A88V/+ and A88V/A88V mice (C), however, epidermis remodeling following wound 
closure generated thicker epidermis in S17F/+ mice compared to controls (B) (*p<0.05, N ≥ 
4). (D) A88V/+ and A88V/A88V mice displayed normal epidermis remodeling following 
wound closure. Scale bar in (B, D) = 10µm. 
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3.4 Discussion 
Connexin-linked skin diseases encompass a diverse array of congenital skin abnormalities 
resiliency to injury. Of particular interest are Cx26 and Cx30 linked skin diseases due to the 
large number of distinct gene mutations that lead to syndromic diseases featuring variable skin 
disorders (Martin and van Steensel, 2015). Patients dominantly expressing the S17F Cx26 or 
A88V Cx30 mutants are diagnosed with KIDS and Clouston Syndrome, respectively, and 
display some dissimilar phenotypes, but share the common characteristic of PPK (Lamartine 
et al., 2000; Richard et al., 2002). Although mutant connexins undoubtedly underpin these 
diseases, specific pathogenic mechanisms are poorly understood and the question of whether 
these patients have wound healing defects has not been explored. In this study, we generated 
a novel tissue-specific S17F Cx26 mouse and used the previously described A88V Cx30 
mouse (Bosen et al., 2014) to address these questions. We found that our novel Cx26K14-S17F/+ 
mice displayed severe PPK and importantly, no decrease in viability. Foot pad epidermis of 
S17F/+ mice displayed increased Cx26 expression and irregular localization profiles of 
epidermal connexins. Furthermore, S17F/+ foot pad epidermis exhibited elevated filaggrin 
expression, but normal expression of keratin 14 and displayed normal proliferation. Primary 
keratinocytes isolated from connexin mutant neonates displayed altered GJIC and migration 
abilities in culture. S17F/+ skin exhibited aberrant epidermal remodeling during wound 
healing but wounds healed at a similar rate to littermate control mice. Lastly, A88V/+ and 
A88V/A88V mice displayed no epidermal phenotypes or differences in wound healing 
compared to controls.  
S17F Cx26 was first linked to KIDS in 2002 (Richard et al., 2002) and is now understood to 
form non-functional gap junction channels or hemichannels but does form hyperactive 
heteromeric hemichannels with wild type Cx26 and Cx43 in culture (Garcia et al., 2015). 
Many syndromic Cx26 mutants fail to form functional channels (Xu and Nicholson, 2013), 
however studies investigating separate KIDS linked mutants reveal that hyperactive 
hemichannels may be a strong etiological factor in KIDS (Garcia et al., 2015; Gerido et al., 
2007; Lee et al., 2009).  A mutant mouse globally expressing S17F Cx26 was found to 
replicate KIDS skin and hearing phenotypes making it a suitable model for KIDS (Schutz et 
al., 2011). However, one drawback with this model was a sharp loss of mouse viability. To 
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alleviate this concern and to directly assess the role of the S17F Cx26 mutant in the epidermis, 
we generated a conditional mutant mouse which expresses the mutant in cells expressing 
keratin 14. We showed here that indeed epidermal expression of S17F Cx26 produced the 
severe PPK seen in KIDS, as well as a short, blunted tail reminiscent of autoamputated digits 
in patients with the Cx26-linked Vohwinkel Syndrome (Maestrini et al., 1999). Furthermore, 
tissue-specific S17F Cx26 mice were generally healthy suggesting that expression of S17F 
Cx26 in other tissues such as liver, kidney, brain, and gut may reduce mouse viability.  
The nearly universal feature of PPK in connexin-linked skin diseases suggests that proper 
GJIC is crucial to maintain highly stratified volar epidermis (Avshalumova et al., 2014). We 
found an imbalance of keratinocyte proliferation and differentiation in foot pad epidermis of 
S17F/+ mice indicated by increased filaggrin expression yet normal expression of Ki67 and 
PCNA. Since filaggrin condenses the keratin cytoskeleton in differentiated keratinocytes, we 
surprisingly observed that suprabasal keratinocytes from S17F/+ foot pad skin did not appear 
to adopt a squamous morphology like those in control epidermis. We also showed that Cx26, 
Cx30, and Cx43 were not confined to specific keratinocyte layers but rather were expressed 
in most keratinocytes, further suggesting deregulated differentiation. Calcium homeostasis in 
the epidermis is thought to have a large impact on keratinocyte differentiation (Adams et al., 
2012), and since Ca2+ mobilizing molecules such as IP3 and ATP are permissible by gap 
junctions and hemichannels, the calcium profile in lesioned epidermis is an attractive, albeit 
difficult element to assess. Interestingly, Bosen and colleagues showed that unlike control 
littermates, global S17F Cx26 mice exhibited large amounts of Ca2+ in the stratum corneum, 
suggesting that S17F Cx26 may disrupt the calcium profile in the epidermis (Bosen et al., 
2015). As some connexin hemichannels are known to release ATP in response to mechanical 
stimulation (Bao et al., 2004; Baroja-Mazo et al., 2013; Saez et al., 2005), it is plausible that 
mutant connexins in the mechanical environment of volar skin could stimulate aberrant 
purinergic signaling that disrupts calcium homeostasis and finally differentiation (Baroja-
Mazo et al., 2013; Martin et al., 2014). Furthermore, lesions of flexural skin regions are also 
commonly observed in KIDS and Vohwinkel Syndrome patients (Avshalumova et al., 2014; 
Coggshall et al., 2013) further supporting mechanically stimulated Cx26 mutants in skin 
pathogenesis. Nevertheless, investigations into the mechanical sensitivity of Cx26 mutants is 
warranted to shed light on this notion.  
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Keratinocytes isolated from our mice demonstrated that physiological levels of S17F Cx26 
led to reduced gap junctional coupling and a similar reduction in collective cell migration. 
Following wounding, undamaged keratinocytes at the wound edge initiate re-epithelialization 
by migrating under the coagulum (Martin, 1997). During this process, a transient reduction of 
cell surface Cx43 favours cell migration by reducing cell-cell adhesion through its binding 
partner zona occludens-1, a protein linked to junctional complexes (Mendoza-Naranjo et al., 
2012). Our results suggest that Cx26, which is thought to only bind an ubiquitin-ligase protein 
(Henzl et al., 2004), can also influence cell migration through direct intercellular 
communication. It is well documented, yet poorly understood why Cx26 and Cx30 are 
transiently upregulated in wound edge keratinocytes (Coutinho et al., 2003; Davis et al., 2013; 
Goliger and Paul, 1995; Kretz et al., 2003), however our results suggest this may generate a 
highly coupled keratinocyte network to optimize collective cell migration. To our surprise, 
S17F/+ cultures also appeared to form fewer and smaller gap junction plaques in light of 
extensive Cx26 gap junction formation in intact S17F/+ epidermis. Reduced gap junction 
formation by S17F Cx26 has however, been reported in HeLa cells (Garcia et al., 2015), 
therefore the disparagement of connexin expression between native epidermis and in vitro 
models highlights the importance of using mutant mouse models in understanding connexin-
linked pathologies.  
Because Cx26 is dynamically regulated during wound healing (Brandner et al., 2004) and 
KIDS patients develop inflammatory skin lesions (Coggshall et al., 2013), it raises questions 
as to whether KIDS patients have abnormal wound healing. There are currently no reports of 
KIDS patients exhibiting wound healing defects, however, the protective care these patients 
require (Coggshall et al., 2013) and the rare nature of this disease argues that a wound healing 
defect may be under reported.  In one study linking Cx26 levels to wound healing, two mouse 
models with persistent epidermal Cx26 expression developed inflammatory lesions and 
wounds which displayed improper remodeling (Djalilian et al., 2006) suggesting that Cx26  
may contribute to the inflammatory and remodeling phases of wound healing. However, the 
S17F/+ mice used in our study displayed no overt wound healing defects, and if this finding 
can be extrapolated to humans, this would suggest that KIDS patients may actually heal 
wounds well. That being said, our findings also suggest that the abnormal keratinocyte 
differentiation required for epidermal remodeling may result in thicker epidermis in the healed 
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skin from KIDS patients. We also demonstrated that hyperkeratotic foot pad epidermis in 
S17F/+ mice had elevated levels of Cx26, suggesting that while unchallenged skin was 
relatively normal, challenged skin by weight bearing or wound healing may provide the 
conditions for S17F Cx26 to disrupt epidermal physiology. Although the exact nature of these 
conditions remains uncertain, our findings support the notion that S17F Cx26 disrupts 
epidermal homeostasis by deregulating keratinocyte differentiation.  
Contrary to our S17F/+ mice, mice globally expressing A88V Cx30 showed almost no 
evidence of skin disease, as the only differential elements were found between A88V/A88V 
and control primary keratinocytes. Since differences arose only once mutant keratinocytes 
were isolated in vitro, this suggests the influence of A88V Cx30 was easily overcome in native 
epidermis where other regulatory are likely at play. Despite differences in genetic background, 
the striking dissimilarity of disease presentation between our mouse models, which express 
functionally similar connexin mutants, suggests that Cx30 may play a minimal role in murine 
epidermis. This notion is supported by the observation that adult Cx30 null mice displayed no 
obvious cutaneous phenotypes (Dere et al., 2003).  
Lastly, Clouston Syndrome is a highly variable disease in humans which suggests that other 
genetic predispositions likely play a large part in disease presentation. For example, Clouston 
Syndrome patients do not generally have hearing loss, however one patient expressing A88V 
Cx30 in addition to a benign Cx26 mutant exhibited mild deafness (Sugiura et al., 2013). 
Despite subtle differences between murine and human epidermis, our findings strongly 
support the generation and assessment of animal models that mirror connexin-linked diseases. 
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4 General Discussion 
A high degree of GJIC is a hallmark of stratified epidermis (Scott et al., 2012). This 
communication is, in part, facilitated by Cx26 and Cx30 gap junctions and it is well known 
that their proper assembly and function is critical for overall skin health (Martin and van 
Steensel, 2015). This thesis compiles the analyses of several connexin-linked skin diseases at 
the level of cells and the intact epidermis. Using transgenic mice, primary keratinocytes, and 
reference cell lines, we examined the cellular characteristics of Cx26 and Cx30 mutants and 
their link to disease. The goal of this work is to elucidate genotype/phenotype relationships of 
distinct connexin mutants as they relate to skin disease and to further understand the 
contribution of these critical molecules in epidermal physiology. Here, I will establish a 
narrative to integrate our findings within the current literature, discuss their clinical 
implications, and present questions for continued investigation. 
4.1 Learning outcomes from transgenic mice 
Limitations to the clinical translatability of cell-based experiments have forced researchers to 
develop animal models to better understand, not only the disease-causing features of connexin 
mutants, but also the role of connexins in normal skin development, healing, and homeostasis. 
Excluding the novel Cx26K14-S17F/+ mouse used in the current study, at least 10 different mouse 
models have been generated as tools to investigate disease-linked connexins (i.e. Cx26, Cx30, 
Cx30.3, Cx31, and Cx43) in skin physiology (Bakirtzis et al., 2003; Bosen et al., 2014; Churko 
et al., 2012; Cogliati et al., 2015; Djalilian et al., 2006; Maass et al., 2004; Mese et al., 2011; 
Schnichels et al., 2007; Schutz et al., 2011). Five of these models feature GJB2 modifications 
that have helped reveal the pathogenesis of KIDS and Vohwinkel Syndrome (Bakirtzis et al., 
2003; Mese et al., 2011; Schutz et al., 2011), whereby a role was proposed for Cx26 in 
epidermal barrier establishment and cutaneous wound healing (Djalilian et al., 2006). In 
addition, Cx30 (Dere et al., 2003) and Cx31 (Plum et al., 2001) null mice displayed no 
cutaneous phenotypes despite their expression in normal healthy skin. While it may therefore 
be compelling to suggest that Cx30 and Cx31 are unlikely candidates for human skin disease, 
in fact, mutations in their genes are linked to Clouston Syndrome, KIDS, and 
erythrokeratoderma variabilis (Lamartine et al., 2000; Lilly et al., 2016; Richard et al., 1998). 
!!
96!
These findings strongly suggest that the presence of a connexin mutant can lead to more 
pathology than the entire absence of the same connexin. Also, the redundancy of GJIC within 
the epidermis likely protects the skin from disease when one connexin is ablated. In our current 
study, we took the approach of using partially characterized connexin mutants to assess their 
impact on the keratinocytes and the epidermis, and further modeled two connexin mutants in 
mouse models of human skin diseases.   
Within the steadily-solidifying paradigm that the scope of disease manifestation is governed 
by the gain- or loss-of function status of Cx26 mutants, we chose to model KIDS using the 
S17F mutant. First pass analyses demonstrated that this mutant conformed to the loss-of-
function grouping as no functional homomeric gap junction channels or hemichannels could 
be observed (Garcia et al., 2015; Lee et al., 2009), however, a careful consideration of gain-
of-function properties neatly investigated by Isaac Garcia and colleagues first demonstrated 
the extended influence of S17F Cx26 on Cx43. Since Cx26 and Cx43 do not normally intermix 
in connexons (Gemel et al., 2004), the curious ability of a non-functional Cx26 mutant to 
trans-dominantly bind Cx43 and form hyperactive complexes is indeed an odd concept in 
connexin biology. Nevertheless, this surprising finding added substantial value to, not only 
our understanding of KIDS, but also the study of connexinopathies, since it demonstrated the 
legitimacy of considering all possible connexin interactions within each disease context. 
Schütz and colleagues took the next step by first introducing the S17F mutant into a mouse 
model (Schutz et al., 2011). This mouse exhibited a dysfunctional epidermal barrier, annular 
tail restrictions, foot pad hyperplasia, and moderate hearing loss, making it a suitable model 
for KIDS (Schutz et al., 2011). However, the global expression of this mutant significantly 
reduced mouse viability, suggesting that tissue-specific knock-in of the mutant Cx26 would 
be beneficial. Thus, using the Cx26+/floxS17F mouse provided by Dr. Willecke, we crossed it 
with a mouse expressing Cre-recombinase driven from the keratin 14 promoter. Herein, we 
demonstrated that epidermis specific expression of S17F Cx26 does not reduce mouse 
viability. We further showed that our mice had an intact epidermal barrier as evaluated by 
using the exact protocol from (Schutz et al., 2011) (refer to Appendix 1). This observation was 
surprising and suggested that perhaps S17F Cx26 expression in embryonic tissues may 
interfere with the establishment of the epidermal barrier in utero and contribute to their poor 
prognosis. Cx26 is indeed expressed in the labyrinth layer of the fetal mouse placenta and 
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interestingly, Cx26 null embryos die by 11 days post coitum due to a placental defect (Gabriel 
et al., 1998). Direct empirical comparison of the development of global mutant and tissue 
specific versions of this mouse may shed light on the nature of the barrier defect and loss of 
viability in global mutant mice, and could further point to developmental complications in 
patients who harbour KIDS mutations. Nevertheless, our novel mutant mouse model allowed 
us to evaluate the influence of the S17F Cx26 on the epidermis alone, and whether this 
expression profile can disrupt wound healing which involves numerous unaffected cell types 
such as fibroblasts, leukocytes, and endothelial cells. 
Primary keratinocytes isolated from S17F/+ mice demonstrated reduced migratory capabilities 
and brought into question whether the mice may exhibit wound healing defects. We therefore 
assessed wound healing using a standard dorsal skin punch biopsy and measured wound 
closure over a period of 13 days. While we found no differences in wound closure between 
S17F/+ mice and controls, we must acknowledge that wound-edge keratinocytes migrate 
beneath the coagulum (Martin, 1997) and were therefore not visible within our assay. 
Furthermore, it is understood that murine wound closure is accomplished primarily by dermal 
fibroblast contraction to bring wound edges in close proximity, and differs from human 
healing which favours keratinocyte re-epithelialization (Reid et al., 2004; Wong et al., 2011). 
The Cx30 A88V mutant mouse used in our study also did not display any wound repair 
defects. Together, one might conclude that patients harboring either of these connexin 
mutations would heal normally from an acute skin wound. To that end, there is no documented 
clinical reports that this cohort of patients have acute skin wounding defects but these events 
are not routinely reported in clinically studies. Since wound closure is somewhat different 
between mice and humans, caution needs to be exercised in translating our mouse findings to 
the human populous.    
In Chapter 2, we demonstrated that the cellular characteristics of Cx26 mutants could predict 
disease outcomes. Our findings suggested that mutations at highly conserved amino acid 
residues (N54K and S183F) can affect connexin binding and trafficking and are linked to 
moderate skin diseases. In addition, mutations that interfere with properties of the channel 
pore (N14K and D50N) led to cell death in culture and are linked to inflammatory skin 
diseases. While we could not determine that cell death was driven by mutant hyperactive 
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hemichannels, there is a body of literature that supports their contribution to cell death as well 
as inflammation (Essenfelder et al., 2004; Garcia et al., 2015; Gerido et al., 2007; Lee et al., 
2009; Levit and White, 2015). This alludes to the question of how hyperactive hemichannels 
may promote inflammation in live epidermis. Conceptually, it can be surmised that since 
hemichannels are conduits for molecular exchange between the cytosol and extracellular 
milieu, their aberrant activity can radically disrupt the extracellular concentration of 
permissible molecular messengers, including inflammatory mediators. Mechanistically, a 
study demonstrated that Cx26-expressing human keratinocytes, generated a strong ATP 
release response following acute exposure to peptidoglycan (PGN) harvested from the 
opportunistic pathogen, S. aureus (Donnelly et al., 2012). Furthermore, they showed that PGN 
challenged keratinocytes expressing KIDS mutants generated even stronger ATP responses 
and led to exaggerated interleukin-6 release, demonstrating the interaction between KIDS 
mutant hemichannels, purinergic signaling, and inflammation. Finally, these responses were 
abolished by the connexin channel blocker, carbenoxolone (Donnelly et al., 2012). In addition 
to forming non-functional gap junctions, S17F Cx26 was shown to potently inhibit 
intercellular dye transfer in cells co-expressing Cx43 (Garcia et al., 2015). This supports our 
finding that S17F/+ primary keratinocytes demonstrated reduced gap junctional coupling. 
While hyperactive hemichannels have been strongly linked to the inflammatory nature of 
KIDS, we wondered if reduced GJIC also contributed to the skin phenotype observed in our 
mice. Fortunately, we can begin to address this question by examining the findings from a 
mouse that was generated to model human Vohwinkel Syndrome by expressing D66H Cx26 
in suprabasal keratinocytes (Bakirtzis et al., 2003). This mutant is not associated with 
hyperactive hemichannels, however, similar to S17F Cx26, it inhibits Cx26 and Cx43 
mediated GJIC (Rouan et al., 2001). The D66H Cx26 mouse is the only Cx26 mutant mouse 
to model a non-inflammatory skin disease and displays scaling skin with a dense, thick corneal 
layer (Bakirtzis et al., 2003). In addition, Cx26 and Cx30 were highly intracellular in 
suprabasal keratinocytes of mutant epidermis and resulted in increased DNA fragmentation 
suggesting that reduced keratinocyte GJIC may deregulate terminal differentiation 
(cornification) (Bakirtzis et al., 2003). Empirical comparison of hyperkeratotic lesions from 
the D66H Cx26 mouse and KIDS mice (S17F and G45E Cx26) may shed light on the influence 
of loss-of-function versus gain-of-function mutants in vivo.  
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Taken together, our findings and the literature involving Cx26 mutants and Cx26 mutant mice, 
suggest that reduced GJIC via intracellular connexin retention or reduced gap junction 
function may result in deregulated keratinocyte differentiation and abnormal skin phenotypes.  
4.2 Therapeutic strategies for connexin linked skin diseases and wound 
healing 
Over a decade of applied research towards connexin-based therapies has generated potential 
improvements for the treatment of several chronic health complications such as 
neuroinflammatory disorders, vasculopathies, ocular disorders, and notably, chronic skin 
wounds (Becker et al., 2016). Using in vitro and animal models of wound healing, some 
researchers have developed successful connexin-based strategies to improve wound healing 
and as a result, have spurred spinoff companies to commercialize novel connexin therapeutics 
(Becker et al., 2016; Ghatnekar and Elstrom, 2013). Of note, Cx43-targeted therapeutic 
compounds developed by CoDa Therapeutics and FirstString Research have delivered 
promising improvements for the healing of chronic venous and diabetic leg ulcers (Ghatnekar 
and Elstrom, 2013) (clinical results update from CoDa). The vast majority of connexin-based 
therapeutics focus on Cx43 largely due to the wealth of prior research demonstrating its 
involvement in many chronic and acute disease states (Nakase et al., 2004; Ormonde et al., 
2012; Sutcliffe et al., 2015; Wang et al., 2007a). CoDa Therapeutics is developing strategies 
to target both Cx43 protein translation using antisense oligodeoxynucleotides, and Cx43 
channel function using targeted mimetic peptides or non-specific small molecules such as 
HCB1019 (Becker et al., 2016). FirstString Research is another company highly focused on 
targeting the C-terminal tail of Cx43 to modulate its function with the intent of improving 
chronic wound healing (Becker et al., 2016; Ghatnekar and Elstrom, 2013).  
To date, there are no targeted  therapies for Cx26 or Cx30-linked skin disease and the current 
clinical treatments rely mainly on early diagnosis and management; especially for severe 
diseases such as KIDS (Coggshall et al., 2013). Maintenance of the skin barrier is of upmost 
importance for such patients since infectious and inflammatory complications are common 
and can be life-threatening (Coggshall et al., 2013). Therefore, patients must treat 
hyperkeratotic plaques with keratolytic and retinoid compounds, frequently moisturize the 
skin, and generously apply antibiotic and antifungal agents (Coggshall et al., 2013; Levit and 
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White, 2015). However, some studies have demonstrated that certain clinically approved small 
molecules such as mefloquin, carbenoxolone, and benzopyran have the ability to block Cx26 
channels demonstrating their potential for therapeutic impact (Cao and Zheng, 2014; Donnelly 
et al., 2012; Levit et al., 2015; Levit and White, 2015). Indeed, the greatest therapeutic value 
may come from attenuating hemichannel activity since their link to diseased states is well 
outlined (Levit and White, 2015), yet their contribution to normal skin physiology is largely 
undetermined. There are, however, no clinical trials for any such therapies due to the 
inadequate number of recruitable patients (Levit and White, 2015). Fortunately for S17F Cx26 
KIDS patients, the Cx43-targetted therapies from CoDa and FirstString may in fact provide 
clinical relief due to the specific involvement of Cx43 in their pathophysiology. In addition, 
the connexin mimetic peptide, Gap19, which targets the intracellular loop of Cx43, inhibits 
Cx43 hemichannels without affecting GJIC as shown in astrocytes (Abudara et al., 2014). It 
would certainly be interesting to assess its effectiveness in S17F Cx26 expressing 
keratinocytes, as perhaps aberrant heteromeric hemichannels may be neutralized without 
disrupting normal Cx43 function.  
As evidence builds for the impact of Cx26 on wound healing, we may begin to see Cx26-
targeted therapeutics emerge in applied clinical research. Since abnormal expression of both 
Cx26 and Cx43 has been established in non-healing diabetic wounds (Becker et al., 2012; 
Wang et al., 2007a), there may be considerable therapeutic value in pursuing Cx26-targeted 
wound therapies, which would undoubtedly provide sufficient patient numbers to organize 
clinical trials. In addition, such therapies may provide relief for patients with congenital Cx26-
linked diseases.  
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Appendix 1 
  
Cx26K14-S17F/+ mice have an intact epidermal barrier 
One of the principle functions of the skin is to provide a protective barrier from environment 
insults including UV radiation and opportunistic pathogens, and to limit water loss. As a first 
pass assessment for water barrier function, a toluidine blue barrier penetration assay was 
performed. Katanya C. Alaga and I contributed equally to this work.  
Methods 
The barrier assay was performed exactly as described in (Schutz et al., 2011). Briefly, P1 pups 
were CO2 euthanized and put through a series of increasing concentration methanol washes, 
followed by decreasing concentration methanol washes. Pups were then stained for 15 minutes 
in an aqueous 0.2% toluidine blue solution. Following staining, the pups were washed several 
times in 90% ethanol, dried, and imaged with an iPhone5. Areas of dark blue/purple staining 
indicated toluidine blue dye penetration and therefore a non-functional water barrier. A 
positive control was performed by making a small laceration to the skin. 
Results  
We found that similar to littermate controls, S17F/+ epidermis did not stain blue indication 
little to no epidermial penetration of the water soluble dye. However, epidermal staining was 
evident in areas of the skin that had ben cut, or treated with acetone which disrupts lipids in 
the epidermal barrier (Tsai et al., 2001). This suggests that neonatal S17F/+ epidermis indeed 
forms an effective water barrier. 
!!
106!
 
Figure A1. P1 neonates were euthanized and submerged in an aqueous 0.2% toluidine blue 
solution for 15 minutes. The absence of epidermal staining of both S17F/+ and controls 
indicates a functional epidermal barrier. A small incision and treatment with acetone were 
used as a positive control.  
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Appendix 2 
Permissions for Artwork Reproduction 
Dr. Jared Churko, a former PhD student in Dr. Dale Laird’s lab, generated a graphic to depict 
the expression of several connexins in adult mouse epidermis. Since I used this graphic in 
Chapter 1 of this thesis, I have included here his written permission from our email 
conversation. 
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